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ABSTRACT

Snyder, Andrew D. Ph.D., Biomedical Sciences Program, Wright State University 2016
A Functional Analysis of the 3’ Regulatory Region of the Immunoglobulin Heavy Chain
Gene

The immunoglobulin heavy chain (IGH) locus is partially responsible for
immunoglobulin (Ig) production in B cells. The human IGH locus contains two 3’
regulatory regions (3’IghRR) that each contain three enhancers, which are thought to
help drive overall transcription of the locus and also influence class switching to
alternative Ig isotypes. The hs1.2 enhancer within the 3’IghRR is polymorphic in humans,
containing a 53 bp invariant sequence (IS) that can be repeated up to four times. In
vitro, the human hs1.2 enhancer is a sensitive target of exogenous chemicals,
particularly 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin), a potent inhibitor of Ig
expression in animal models. The IS polymorphisms have also been associated with
many immunological disorders in human patients. Therefore, understanding the role of
the hs1.2 polymorphisms could be invaluable to human health. To investigate the
function of the hs1.2 polymorphism, a mutational analysis was performed in a luciferase
assay system to assess the contribution of each hs1.2 transcription factor binding site to
overall hs1.2 activity. From this analysis, it is clear that each transcription factor binding
site individually contributes to the changing activity of the hs1.2 enhancer with B-cell
iii

stimulation. Surprisingly, results also indicate that TCDD likely acts on the hs1.2
enhancer through NF1 binding sites rather than dioxin response elements. However,
further studies using luciferase reporters containing additional 3’IghRR elements call
into question the value of luciferase assays in assessing 3’IghRR function. In order to
study the endogenous 3’IghRR directly, the CRISPR/Cas9 gene editing system was used
to modify the hs1.2 enhancer in the human 3’IghRR. Using a single CRISPR/Cas9 plasmid
targeting the polymorphic hs1.2 invariant sequence (IS) repeats in a human B-cell line
has successfully resulted in clonal populations containing a reduced number of IS
repeats. Experiments with these cells have revealed that changing the combination of
hs1.2 polymorphisms decreases the expression of some Ig isotypes while increasing
others. Significantly, the α1 hs1.2 enhancer has a surprisingly large effect on expression
of ε transcripts, suggesting this enhancer should be investigated as a target of small
molecule therapy in allergy sufferers.
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I. Literature Review
The production of antibodies, also called immunoglobulins (Ig), is a complex and
highly regulated process that starts during B-cell maturation. The stages of B-cell
maturation are characterized by the DNA recombination events that must occur in order
to produce functional Ig. Functional Ig is formed by linking two light chain and heavy
chain proteins that come to together to form a “Y” shaped molecule. The heavy chain of
Ig (IGH) contains a variable region at one end, which forms one half of the antigen
binding site, and a constant region at the other that determines how the molecule will
function in different immunological contexts. The heavy chain of Ig is expressed by the
IGH gene, which has a complex structure with the variable heavy chain (VH) promoter at
the 5’ end followed by the variable (V), diversity (D), and joining (J) regions which
encode the variable end of the IGH molecule. After the VDJ regions there is an intronic
enhancer, Eµ, followed by the constant regions (i.e., C ϒ, C ε, etc.) that encode the
different isotypes, or classes, of Ig and then the 3’ IGH regulatory region (3’IghRR) which
is the most 3’ end of the gene (Fig. 1).
Before a B cell fully differentiates to express antibodies, it gets activated in either
a T cell dependent or independent response. Once activated, either by T cells or an
antigen, the B cell differentiates into a plasma cell and begins secreting large amounts of
Ig. In order for productive transcripts of IGH to be produced, the IGH gene must first
undergo VDJ recombination. VDJ recombination is a process used to assemble the
separated V, D, and J segments and ensures the diversity of antigen binding sites in Ig.
This process begins with D-J rearrangement in the pre- B-cell stage followed by V-DJ
1
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Figure 1. Human versus mouse IGH locus (A). The IGH locus is highly homologous between mice
and humans, but still contains significant structural differences. The human locus contains two
3’IghRRs whereas the mouse only contains one. The mouse locus also contains an additional
enhancer. A second diagram of the human locus (B) reflects the overall size of the human IGH
locus drawn roughly to scale. The broken line following the Eµ enhancer represents a change in
scale between the first part of the diagram and the rest.
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Figure 2. Human IGH locus with hs1.2 enhancer. The hs1.2 enhancer is densely packed with
transcription factor binding sites. A 53 base pair invariant sequence (IS) is polymorphic and can
be repeated up to four times.

3

rearrangement in the pro-B-cell stage. This process is mediated by Rag1/2 and involves
making a double strand break in the DNA which necessitates activation of the DNA
repair machinery (reviewed in (Soulas-Sprauel et al., 2007)). Any B-cells that fail to
recombine successfully undergo apoptosis and are eliminated. During an active immune
response, in activated (stimulated) B cells, VDJ recombination can be followed by
somatic hypermutation of the variable region which further increases the affinity of the
antibody for the activating antigen. In the later stages of the humoral immune response
the Ig heavy chain locus can undergo class switch recombination. Whenever a B cell is
going to produce a type of Ig other than IgM the cell needs to undergo class switch
recombination in order to alter the effector function of the Ig without changing its
antigen specificity. This step involves the repetitive switch regions upstream of each
constant region and is initiated by activation-induced cytidine deaminase. Breaks are
introduced into the DNA at the two switch regions, which then fuse together, and the
intervening region is excised as a circular piece of DNA which then gets digested (Fig. 3)
(Dudley, Chaudhuri, Bassing, & Alt, 2005; Soulas-Sprauel et al., 2007).
A major regulator of transcription of IGH as well as class switch recombination
and somatic hypermutation is the 3’IghRR, a roughly 20 kb region found downstream of
the constant regions (Lieberson, Ong, Shi, & Eckhardt, 1995; Mills, Harindranath,
Mitchell, & Max, 1997; Pinaud et al., 2001; Pinaud et al., 2011; Vincent-Fabert et al.,
2010). The mouse 3’IghRR is composed of four DNase I hypersensitive sites that exhibit
enhancer activity, while in humans there are only three enhancers, which are
duplicated. The human 3’IghRRs are distinguished as the α1 3’IghRR, which sits
4

Figure 3. Class switch recombination. During class switch recombination the 3’IghRR is thought
to drive transcription of a sterile germline transcript which increases the availability of the
switch regions (grey ovals). When the switch regions are joined together a double strand break
occurs and the intervening sequence is excised as a switch circle. The new constant region (ε in
this example) takes the place of the µ constant region and a functional transcript is created from
the recombined locus. Figure reproduced from (Burra, 2015).
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downstream of Cα1, and the α2 3’IghRR, which sites downstream of Cα2 and marks the
3’ end of the IGH gene (Mills et al., 1997; Pinaud, Aupetit, Chauveau, & Cogne, 1997).
These regions are weak enhancers individually, but together exert strong control over
transcription and class switch recombination of IGH (Chauveau, Pinaud, & Cogne, 1998).
The enhancers are dispersed among long stretches of highly repetitive, somewhat
palindromic sequences which may also be functional, although this idea has yet to be
systematically tested (D'Addabbo, Scascitelli, Giambra, Rocchi, & Frezza, 2011). The
3’IghRR enhancers each contain numerous transcription factor binding sites for widely
studied transcription factors such as NFκB, Oct, and AP-1 (Pinaud et al., 2011). The
enhancer that contains the most transcription factor binding sites is hs1.2, which
contains a 53 bp invariant sequence that is polymorphic, meaning it can appear a
different number of times in different people (Fig. 2) (Chauveau et al., 1998; Guglielmi,
Truffinet, Magnoux, Cogne, & Denizot, 2004; Mills et al., 1997; Pinaud et al., 1997). This
invariant sequence can be repeated up to four times (Fig. 2), and these repeats have
been associated with some human disease states (Chauveau et al., 1998; Cianci et al.,
2008; Frezza et al., 2009; Frezza et al., 2007; Mills et al., 1997; Pinaud et al., 1997;
Tolusso et al., 2009). The polymorphism in the human hs1.2 enhancer does not exist in
mice, and there are other species differences between mice and humans. For example,
the mouse 3’IghRR contains Pax5 binding sites, while the human 3’IghRR does not
(Pinaud et al., 2011). The significant structural differences between the mouse and
human locus, coupled with the presence of different assortments of transcription factor
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binding sites between the two species, could indicate that the 3’IghRR functions
differently in the two species.
The mouse 3’IghRR is a sensitive target of exogenous chemicals and treatment
with these chemicals can lead to altered Ig expression (Fernando, Ochs, Liu, ChambersTurner, & Sulentic, 2012; Sulentic, Kang, Na, & Kaminski, 2004; Wourms & Sulentic,
2015). TCDD, a common environmental pollutant, is a potent inhibitor of Igh in animal
models (reviewed in (Hanieh, 2014; Quintana, 2013)). Humans exposed to TCDD exhibit
a variety of toxicological effects including chloracne, liver dysfunction, carcinogenesis,
and cardiovascular diseases (Marinkovic, Pasalic, Ferencak, Grskovic, & Stavljenic
Rukavina, 2010; McGregor, Partensky, Wilbourn, & Rice, 1998; Pesatori et al., 2003; Yu,
Guo, Hsu, & Rogan, 1997; Zober, Ott, & Messerer, 1994). The effect of TCDD on the
human immune system, particularly in B cells, is still largely unknown. However, in
mouse models TCDD is a potent immunosuppressant (Denison & Nagy, 2003; Denison,
Pandini, Nagy, Baldwin, & Bonati, 2002). Many studies have shown that TCDD binds to
the aryl hydrocarbon receptor (AhR), a ligand activated transcription factor which can
bind to a variety of synthetic and natural ligands (Y. Fujii-Kuriyama & Mimura, 2005;
Noakes, 2015; Schecter, Birnbaum, Ryan, & Constable, 2006). TCDD is the strongest AhR
ligand currently known (C. Vogel et al., 1997). Once bound to TCDD, the AhR sheds its
associated chaperone proteins and translocates to the nucleus where it binds to the AhR
nuclear translocator (ARNT) (Yoshiaki Fujii-Kuriyama & Kawajiri, 2010; Y. Fujii-Kuriyama
& Mimura, 2005). The TCDD-AhR-ARNT complex then binds to dioxin response elements
(DRE) found in sensitive genes (Fig.2) (Yoshiaki Fujii-Kuriyama & Kawajiri, 2010; Y. Fujii7

Kuriyama & Mimura, 2005). This molecular pathway has been most extensively studied
in relation to the DRE binding sites in CYP1A1, but recent work has also shown AhR
binding to the DRE within the hs1.2 enhancer of the mouse 3’IghRR following TCDD
treatment (Y. Fujii-Kuriyama & Mimura, 2005; Wourms & Sulentic, 2015). Rodents
display a variety of innate and acquired immune-related disturbances following acute or
chronic exposure to low levels of TCDD (Holsapple, Morris, Wood, & Snyder, 1991; Vos,
De Heer, & Van Loveren, 1997). TCDD affects B-cell maturation, activation,
differentiation and to a lesser extent proliferation (Sulentic & Kaminski, 2011).
Importantly, this work was done in mouse B cells and it is currently unknown if the same
mechanism is at work in human B cells. TCDD has also been shown to inhibit
differentiation of B cells by altering DNA methylation patterns (McClure, North,
Kaminski, & Goodman, 2011).
Past research shows that mouse 3’IghRR transcriptional activity in LPSstimulated CH12.LX mouse B cells is inhibited by TCDD (Sulentic et al., 2004). This effect
parallels TCDD-induced inhibition of μ heavy chain gene expression and IgM production
(Sulentic, Holsapple, & Kaminski, 2000). The hs4 and hs1.2 enhancers each contain a
DRE-like site that demonstrates TCDD-inducible binding of AhR/ARNT by EMSA-Western
and ChIP analysis (Salisbury & Sulentic, 2015; Sulentic et al., 2000), which supports at
least a partial role of DRE-dependent regulation; however, the AhR is known to interact
directly and indirectly with a number of different transcription factors such as AP-1, NFκB, and SP-1 (Kobayashi, Sogawa, & Fujii-Kuriyama, 1996; Suh et al., 2002; Tian, 2009;
Tian, Ke, Denison, Rabson, & Gallo, 1999). Even though a link between the AhR and Oct
8

remains unclear, a high frequency of Oct sites was found in AhR-responsive genes using
a genetic algorithm, thus suggesting a potential role for Oct in mediating a response to
TCDD (Kel et al., 2004). Interestingly, Oct and NF-κB act as repressors of mouse hs1.2
activity in mature, non-activated B cells but become activators of mouse hs1.2 activity in
plasma cells suggesting a cooperative interaction between Oct and NF-κB and a
potential modulation by TCDD or the AhR (Michaelson et al., 1996; Salisbury & Sulentic,
2015; Wourms & Sulentic, 2015).
A few studies have been published regarding epigenetics of the 3’IghRR. Studies
have shown that histones H3 and H4 in hs4 are demethylated during B-cell maturation
and hs3b and hs1.2 are demethylated after B-cell activation (Garrett et al., 2005).
Further chromatin immunoprecipitation experiments have shown a stepwise activation
of the 3’IghRR with histone H3 in hs4 becoming acetylated in the pro- and pre- B-cell
stages while hs3, hs1.2, and hs3b become acetylated in mature B-cells (Garrett et al.,
2005). However, these observations are difficult to apply to the general function of the
3’IghRR enhancers, because the effect of deletions of these enhancers in various model
systems do not seem to correlate to specific stages of B-cell maturation. In fact,
deletions of each enhancer individually in mouse models showed no significant
alteration in transcription of any Igh isotype except IgM (Bebin et al., 2010; Cogne et al.,
1994; Manis et al., 1998; Vincent-Fabert et al., 2009). In contrast, deletion of the
3’IghRR enhancers in pairs resulted in a marked decrease in transcription and class
switch recombination (Dunnick et al., 2009; Dunnick, Shi, Graves, & Collins, 2005).
Deletion of the entire mouse 3’IghRR resulted in a broad reduction of Igh expression,
9

class switch recombination, and alterations to somatic hypermutation (Vincent-Fabert
et al., 2010). Chromosome conformation capture experiments have shown that the
3’IghRR enhancers physically interact with the VH promoter and the Eµ intronic
enhancer, although Eµ is dispensable for the interaction of the 3’IghRR with the
promoter (Ju, Chatterjee, & Birshtein, 2011). The looping of the 3’IghRR also leads it to
interact with the JH region, and this looping occurred independently of expression of
several transcription factors which bind to the 3’IghRR (Ju et al., 2011). To reiterate,
much of this research was conducted using mouse models, but due to the significant
differences between the mouse and human 3’IghRR, it is difficult to know how much of
it translates between the two species. Therefore, more research in human model
systems is clearly necessary, but new tools are needed to conduct these studies since
technical limitations and lack of appropriate cellular models have hampered study
progress. Recent advances in molecular biology have made it possible to create genetic
modifications that were impossible just a few years ago. Specifically, the development
of the CRISPR genetic editing system makes it possible to create highly specific, targeted
genetic edits in virtually any living cell (He et al., 2015; Li et al., 2015; Mali et al., 2013;
Zhang et al., 2015; Zheng et al., 2014). Taking advantage of the development of this new
gene editing technique makes it possible to study the function of the endogenous
human 3’IGHRR in a way that has never been done before so that significant gaps in
knowledge about the human 3’IGHRR can begin to be addressed.
In spite of the decades of research conducted on the Ig heavy chain locus there
are still significant unknowns associated with the function of this gene. The functional
10

significance of the many structural differences between the mouse and human 3’IghRR
is still unknown. For example, the duplication of the 3’IghRR in the human locus is
thought to be functionally significant, but no studies have investigated the specific roles
of the α1 versus α2 3’IghRR in antibody expression. Logically, since the first 3’IghRR is
lost in the switch circle during class switch recombination to downstream constant
regions, it seems likely that the second 3’IghRR should be able to compensate for loss of
the first. However, no studies have been conducted to support this theory. Another
major structural difference between the mouse and human 3’IGHRR is found in the
hs1.2 enhancer. The human hs1.2 enhancer contains a 53 bp invariant sequence (IS)
which is polymorphic and can be repeated up to four times. This polymorphism does not
exist in the mouse hs1.2 enhancer, so all studies involving the mouse Igh locus have
missed any functional significance of the human polymorphism. The human hs1.2
enhancer also contains a completely different complement of transcription factor
binding sites, which raises the possibility that the mouse and human hs1.2 enhancers
could function in different ways. The goal of this research is to confirm the findings of
the animal studies by demonstrating that the human 3’IGHRR is a powerful regulator of
IGH expression while also attempting to determine the functional significance of the
hs1.2 polymorphism.

Significance
Polymorphisms within the α1 3’IghRR hs1.2 enhancer have been associated with
a host of immune disorders such as rheumatoid arthritis, dermatitis herpetiformis,
11

systemic sclerosis, and celiac disease (Cianci et al., 2008; Frezza et al., 2009; Frezza et
al., 2007; Tolusso et al., 2009). Also, chromosomal translocations between the 3’IghRR
and c-myc have been known to lead to cancer, especially Burkitt’s lymphoma (J. Wang &
Boxer, 2005). Since genetic variations in the 3’IghRR are associated with so many human
diseases, a better understanding of its function and regulation by exogenous chemicals
could be immensely beneficial to human health. Furthermore, this research could lead
to better or more targeted treatments of immunological conditions associated with
3’IghRR polymorphisms or translocations because it is thought to be such a potent
regulator of overall IGH expression based on animal studies. For example, allergy
treatments in particular might be improved by a better understanding of the 3’IghRR.
Establishing how the human 3’IghRR works, in particular how it responds to exogenous
chemicals such as TCDD, could benefit many people suffering from an immunological
medical condition and even some cancers.
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II. Specific Aim 1
Specific Aim 1 Rationale
The 3’IghRR has been extensively studied in mouse model systems and its
functions as a key regulator of transcription, class switch recombination, and somatic
hypermutation are well established (Pinaud et al., 2011). However, relatively little work
has been done to evaluate the human 3’IghRR. There are significant species differences
between the human and mouse IGH genes, the most obvious of which is the duplication
of the human 3’IghRR. Other differences between mouse and human 3’IghRR include
significant differences in the transcription factor binding sites within the individual
enhancers that make up the 3’IghRR and the presence of additional DNase I
hypersensitive sites downstream of the enhancers in the mouse 3’IghRR (Mills et al.,
1997; Pinaud et al., 1997; Sepulveda, Garrett, Price-Whelan, & Birshtein, 2005).
Although most of the literature appears to assume the mouse and human 3’IghRRs
function in the same way, the significant structural differences between the two species
suggest there could also be functional differences. These facts make it difficult to apply
murine research to the human 3’IghRR, which reinforces the necessity of more clearly
establishing how the human 3’IghRR operates.
The human hs1.2 enhancer within the 3’IghRR has a completely different
complement of transcription factor binding sites than the mouse hs1.2 enhancer. This
pronounced difference in transcription factors could suggest a species difference in how
the hs1.2 enhancer operates, and to begin to understand this potential difference it is
necessary to evaluate the function of the hs1.2 enhancer’s many transcription factor
binding sites.
13

Figure 4. The hs1.2 luciferase reporter plasmid. The hs1.2 luciferase reporter plasmid contains
an hs1.2 enhancer with a single polymorphic invariant sequence (IS) and the variable heavy
chain promoter (V H). Transcription factor binding sites in the hs1.2 enhancer were mutated
through site directed mutagenesis and used in transfection studies.
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Experiments for specific aim 1 will utilize the CH12.LX mouse B cell line. The
CH12.LX cell line was derived from the murine CH12 B-cell lymphoma arising in a B10.H2aH-4bp/Wts (2a4b) mouse. The CH12.LX cell line was characterized by Bishop and
Haughton (1986) and has been used extensively in immunological and toxicological
research (Haughton, Arnold, Bishop, & Mercolino, 1986). The CH12.LX cells have high
AhR expression and a functional AhR signaling pathway. These cells also demonstrate a
sensitive inhibition of LPS-induced Ig expression by TCDD as seen in vivo and in primary
B cells (Sulentic, Holsapple, & Kaminski, 1998; Sulentic et al., 2000). To determine the
relative contribution of each transcription factor binding site to the activity of the
human α1 hs1.2 enhancer, site directed mutagenesis of a luciferase reporter containing
the human 3’IghRR α1 hs1.2 enhancer was conducted and the resultant mutants were
analyzed under different treatment conditions in the well-characterized CH12.LX mouse
B-cell line to test the hypothesis that the DRE within the hs1.2 enhancer mediates the
enhancer’s response to TCDD and that transcription factor binding sites outside the IS
polymorphism have a stronger effect on overall and stimulation-induced transcriptional
activity.

Specific Aim 1 Results
Mutations of the binding sites outside of the IS have opposite effects
The AP1.Ets binding site is the most 5’ transcription factor binding site in the
hs1.2 enhancer and is not one of the sites repeated in the hs1.2 polymorphism. There is
15

a single nucleotide difference between the mouse and human AP1.Ets site, which causes
the human AP-1 site to match the consensus sequence (Mills et al., 1997). In the murine
hs1.2 enhancer the AP1.Ets site confers responsiveness to B-cell receptor cross-linking
and has a functional role in 3’IghRR activity (Grant, Thompson, & Pettersson, 1995).
Following IgM receptor activation of primary B lymphocytes or BAL-17 cells, a mouse B
cell lymphoma cells line, enhancer activation was concurrent with recruitment and
binding of nuclear factor of activated B cells (NFAB) to the AP1.Ets site (Grant et al.,
1995). Correspondingly, mutation of the AP1.Ets site had the most dramatic impact on
overall transcription as compared to the other transcription factor binding site
mutations. The mutation of the AP1.Ets site nearly eliminated overall transcriptional
activity by the hs1.2 enhancer. This was true in both LPS-stimulated and unstimulated
cells. Interestingly, TCDD-induced fold-activation of the enhancer was unaffected by this
mutation. This result suggests the AP1.Ets site strongly regulates hs1.2 enhancer activity
but plays no role in TCDD-induced activation of this enhancer (data not shown, refer to
(Ochs, 2012)).
Like the AP1.Ets site the transcription factor octamer (Oct) is located 5’ of the
invariant sequence (IS). Oct contributes to mouse hs1.2 enhancer activity and is
conserved between mouse and human (Mills et al., 1997). In B cells, Oct in collaboration
with G-rich, κB-like motifs and Pax5 repress transcription of the murine hs1.2 enhancer
(Singh & Birshtein, 1996). Our results suggest Oct may play a similar role in the human
hs1.2 enhancer because mutation of the Oct binding site increased overall activity of the
hs1.2 enhancer. Mutation of the Oct binding site also significantly increased TCDD16

induced activation of the hs1.2 enhancer in terms of fold change, suggesting that the
Oct site suppresses the TCDD response. However, this effect was only observed in
unstimulated cells, which indicates some aspect of TLR-4 signaling can override the
effect of Oct on TCDD-induced activation (data not shown, refer to (Ochs, 2012)).

Mutation of any binding site within the IS increases overall transcriptional activity by the
hs1.2 enhancer
There are two SP-1 binding sites present in the human hs1.2 enhancer which are
found straddling either end of the approximately 53 bp polymorphic IS. These SP-1 sites
are not conserved between the mouse and human locus, and are not repeated in the
human polymorphisms. There is no information available about the role SP-1 plays in
IGH regulation, but SP-1 is often associated with other transcription factors, especially
those which have binding sites in the hs1.2 enhancer (Kobayashi et al., 1996; Nehls,
Rippe, Veloz, & Brenner, 1991; Rafty, Santiago, & Khachigian, 2002; Safe & Abdelrahim,
2005; Tapias, Ciudad, & Noe, 2008; F. Wang, Wang, & Safe, 1999). In particular, other
groups have shown interactions between SP-1 and NF1 and also between SP-1 and AhR
(Kobayashi et al., 1996; Nehls et al., 1991; Rafty et al., 2002; F. Wang et al., 1999).
Mutation of either SP-1 site significantly increased overall transcriptional activity by the
hs1.2 enhancer but had no significant effect on the TCDD-induced activation of the
enhancer in terms of fold change over the vehicle control (Fig. 5 and 6).
The IS within the hs1.2 enhancer contains four transcription factor binding sites;
AP-1, NF1, NF-κB, and a DRE core binding motiff. Most of these sites are repeated up to
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Figure 5. Mutational analysis of the SP1 transcription factor binding sites within the hs1,2
enhancer. CH12.LX cells were transiently transfected with the hs1.2 reporter plasmid with the 5’
SP1 site (SP1.1) mutated. Transfected cells were either cultured in the absence of any additional
treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD
(0.001-10.0 nM) in the absence or presence of LPS (0.1 μg/ml) stimulation for 24 hours.
Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative light units
normalized to transfection efficiency (top graph.) Fold change is represented on the y-axis
relative to the respective DMSO vehicle control and was generated from averaging the means of
at least three independent experiments (bottom graph.) Comparisons between treatment
groups of the same plasmid were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post test. One, two, or three asterisks (*) denote significance compared to
the corresponding vehicle control at p<0.05, p<0.01, or p<0.001 respectively. Comparisons
between reporter plasmids were analyzed using a 2-way ANOVA followed by a Bonferroni posttest. “†”, “††”, “†††”, denote significant differences between reporter plasmids for each
treatment at p<0.05, p<0.01 and p<0.001, respectively. A vertical line represents a significant
difference between reporter plasmids for all treatment groups of at least p<0.01.
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Figure 6. Mutational analysis of the SP1 transcription factor binding sites within the hs1,2
enhancer. CH12.LX cells were transiently transfected with the hs1.2 reporter plasmid with the 3’
SP1 site (SP1.2) mutated. Transfected cells were either cultured in the absence of any additional
treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD
(0.001-10.0 nM) in the absence or presence of LPS (0.1 μg/ml) stimulation for 24 hours.
Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative light units
normalized to transfection efficiency (top graph.) Fold change is represented on the y-axis
relative to the respective DMSO vehicle control and was generated from averaging the means of
at least three independent experiments (bottom graph.) Comparisons between treatment
groups of the same plasmid were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post test. One, two, or three asterisks (*) denote significance compared to
the corresponding vehicle control at p<0.05, p<0.01, or p<0.001 respectively. Comparisons
between reporter plasmids were analyzed using a 2-way ANOVA followed by a Bonferroni posttest. “†”, “††”, “†††”, denote significant differences between reporter plasmids for each
treatment at p<0.05, p<0.01 and p<0.001, respectively. A vertical line represents a significant
difference between reporter plasmids for all treatment groups of at least p<0.01.
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four times in the IS sequence polymorphisms. Since previous studies have demonstrated
an AhR-dependant activation of the human hs1.2 enhancer by TCDD (Fernando et al.,
2012), the identification of a DRE core motif in the repeated IS sequence seemed a
plausible route for this effect. Additionally, it has been shown that AP-1 and NF-κB are
affected by the AhR or TCDD through cross-talk interactions or altered binding and
expression, so mutation of these sites was also expected to affect TCDD-induced
enhancer activation (Suh et al., 2002; Tian, Rabson, & Gallo, 2002). Surprisingly, none of
these sites when mutated were found to significantly affect TCDD-induced activation,
not even the DRE (Fig. 7 and (Ochs, 2012)). However, mutation of these binding sites did
significantly, but modestly, increase overall transcriptional activity of the hs1.2
enhancer, which stands in stark contrast to our previous study that found deletion of
the IS lead to a large decrease in overall hs1.2 activity (Fernando et al., 2012). These
results underscore the complexity of the hs1.2 transcriptional regulation and suggest
that TCDD modulates hs1.2 enhancer activity through a non-canonical pathway.

Mutation of the NF1 binding site reduces TCDD-induced activity but has little effect on
overall transcriptional activity
The nuclear factor 1 binding site is located in the middle of the IS and is repeated
in the hs1.2 polymorphisms. Little is known about the role of NF1 in IGH regulation, but
there is evidence that NF1 functions cooperatively with other hs1.2 transcription
factors, in particular SP-1 (Nehls et al., 1991). However, some of this work has been
contradictory (Rafty et al., 2002). To our knowledge, no one has shown a direct
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relationship between NF1 and AhR. In the current study, mutation of the NF1 site had
little effect on overall transcriptional activity of the hs1.2 enhancer as compared to
mutation of any of the other transcription factor binding sites. However, an unexpected
result of the NF1 mutation was a significant reduction in TCDD-induced activation of the
hs1.2 enhancer in terms of fold change over the vehicle control (Fig. 8). Interestingly,
this reduction only occurred in LPS-stimulated B cells and not in unstimulated cells. This
result further supports our conclusion that TCDD affects hs1.2 enhancer activity through
a non-canonical AhR-mediated pathway.
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Figure 7. Mutational analysis of the DRE transcription factor binding site within the hs1,2
enhancer. CH12.LX cells were transiently transfected with the hs1.2 reporter plasmid with the
DRE site mutated. Transfected cells were either cultured in the absence of any additional
treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD
(0.001-10.0 nM) in the absence or presence of LPS (0.1 μg/ml) stimulation for 24 hours.
Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative light units
normalized to transfection efficiency (top graph.) Fold change is represented on the y-axis
relative to the respective DMSO vehicle control and was generated from averaging the means of
at least three independent experiments (bottom graph.) Comparisons between treatment
groups of the same plasmid were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post test. One, two, or three asterisks (*) denote significance compared to
the corresponding vehicle control at p<0.05, p<0.01, or p<0.001 respectively. Comparisons
between reporter plasmids were analyzed using a 2-way ANOVA followed by a Bonferroni posttest. “†”, “††”, “†††”, denote significant differences between reporter plasmids for each
treatment at p<0.05, p<0.01 and p<0.001, respectively. A vertical line represents a significant
difference between reporter plasmids for all treatment groups of at least p<0.01.
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Figure 8. Mutational analysis of the NF1 transcription factor binding site within the hs1,2
enhancer. CH12.LX cells were transiently transfected with the hs1.2 reporter plasmid with the
NF1 site mutated. Transfected cells were either cultured in the absence of any additional
treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD
(0.001-10.0 nM) in the absence or presence of LPS (0.1 μg/ml) stimulation for 24 hours.
Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative light units
normalized to transfection efficiency (top graph.) Fold change is represented on the y-axis
relative to the respective DMSO vehicle control and was generated from averaging the means of
at least three independent experiments (bottom graph.) Comparisons between treatment
groups of the same plasmid were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post test. One, two, or three asterisks (*) denote significance compared to
the corresponding vehicle control at p<0.05, p<0.01, or p<0.001 respectively. Comparisons
between reporter plasmids were analyzed using a 2-way ANOVA followed by a Bonferroni posttest. “†”, “††”, “†††”, denote significant differences between reporter plasmids for each
treatment at p<0.05, p<0.01 and p<0.001, respectively. A vertical line represents a significant
difference between reporter plasmids for all treatment groups of at least p<0.01.
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Figure 9. Summary of the impact of specific mutations on human hs1.2 reporter activity. Up or
down arrows means more or less overall transcriptional activity compared to the non-mutated
plasmid. Treatment with TCDD or LPS caused an increase in reporter activity regardless of which
binding site was mutated. Only the mutated NF1 binding site lead to a significant decrease in the
TCDD response, and only when the cells were stimulated by LPS.
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III. Specific Aim 2
Specific Aim 2 Rationale
Most current knowledge of the 3’IghRR has been derived from studies in mouse
models due to the difficulty of studying this region in human cells. The human 3’IghRR
duplication makes it difficult to discern which 3’IghRR is responsible for IGH expression.
Also, the vast amount of sequence identity between the α1 and α2 3’IghRR has made it
nearly impossible to make specific deletions to either region using traditional genetic
editing methods that require long arms of homology. For these reasons most of the
human 3’IghRR studies have been based on reporter plasmids (Pinaud et al., 2011).
Unfortunately, these reporter plasmid studies have had significant deficiencies. So far all
of these studies have either used separate plasmids for each enhancer, or have all the
enhancers strung together without the intervening sequences (Fernando et al., 2012;
Mills et al., 1997; Sulentic et al., 2004). Neither one of these situations reflects how the
enhancers are situated in the cell, where the enhancers are thought to cooperatively
interact and are separated by many kilobases of intervening sequence. Furthermore,
studies involving the mouse and human hs1.2 enhancer have shown significantly
different results that appear to be species dependent (Fernando et al., 2012). The
mouse hs1.2 enhancer increases activity in response to B-cell stimulation and decreases
activity in response to TCDD, which is consistent with theories of 3’IGHRR function since
B-cell stimulation is expected to increase 3’IGHRR-driven transcription and TCDD is a
known immunosuppressant in rodents. However, the human hs1.2 enhancer actually
decreases activity in response to B-cell stimulation and increases activity in response to
TCDD, which is exactly the opposite of the expected outcome (Fig. 10 and (Fernando et
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al., 2012). The human hs1.2 enhancer also reacts differently to B-cell stimulation
depending on if it’s being studied in mouse or human B-cells (Fig. 10). One possible
explanation for these unexpected results could be that the hs1.2 enhancer was taken
out of its natural context i.e. lacking the other two enhancers. It is also possible that the
intervening sequence between the enhancers could be functional since it contains
multiple potential transcription factor binding sites as well as unique repetitive
nucleotide sequences that some scientists believe might contribute to essential
secondary structures that contribute to 3’IghRR function (Giambra et al., 2005). Indeed,
recent work using knockout mice that lack these intervening sequences have shown
they have a significant effect on Ig expression (Garot et al., 2016).
Experiments in support of this specific aim utilized the human B-cell line CL-01
and the mouse B cell line CH12.LX. The CL-01 cell line expresses surface IgM and IgD,
secretes monoclonal antibodies, and can be induced to undergo class switch
recombination to multiple isotypes by TLR 9 stimulation or CD40L plus IL-4 (Cerutti et
al., 1998; Zan et al., 1999). This is a Burkitt’s lymphoma cell line, bearing the
chromosomal translocation of one 3’IghRR allele to the c-myc gene. It is currently
unknown which allele has translocated to c-myc, which could complicate data
interpretation. Regardless, the CL-01 cell line is better suited to this project than other
human B-cell lines such as IM-9 due to the CL-01’s ability to respond to stimulation and
undergo class switch recombination, which are essential for this study. The unexpected
results from human hs1.2 enhancer reporter studies combined with the lack of studies
with the enhancers in their natural context coupled with the recent work on knockout
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mice provides an excellent rationale for creating a new reporter plasmid with the
human enhancers that includes more of the human 3’IghRR sequence to test the
hypothesis that a human 3’IghRR reporter containing all the enhancers along with the
intervening sequences between the enhancers will exhibit increased activity in response
to B-cell stimulation and decreased activity in response to TCDD in human cells.
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Figure 10. The hs1.2 reporter plasmid in mouse versus human cells. When the hs1.2 reporter
plasmid is transfected into mouse CH12.LX cells which are stimulated by LPS, activity increases
relative to unstimulated cells. Treatment with TCDD increases activity in both stimulated and
unstimulated mouse cells. When the same reporter plasmid is transfected into human CL-01
cells which are stimulated with CD40L and IL-4, activity decreases relative to unstimulated cells.
TCDD treatment increases activity under both conditions.
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Figure 11. The pGL3.hs3-1.2.4 luciferase reporter plasmid. This new human 3’IghRR reporter
plasmid contains more of the 3’IghRR, including the entire intervening sequence between hs3
and hs1.2. The hs1.2 enhancer contains two repeats of the polymorphic region. The hs4
enhancer follows directly after the hs1.2 enhancer. The intervening sequence between hs3 and
hs1.2 contains long nucleotide repeats (microsatellite repeats) and additional DRE and AP-1
transcription factor binding sites. Variations of this plasmid were created which contained either
the γ3 or ε intronic promoters instead of the V H promoter. Other variations of this plasmid
excluded the hs4 enhancer.
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Specific Aim 2 Results
Nomenclature
For the sake of clarity, the nomenclature used to describe the new 3’IghRR
reporter plasmids will follow a specific format. The name of each reporter will include
the type of promoter in the plasmid as well as a reference to how much of the 3’IghRR is
included in the plasmid. For example, the reporter plasmid that includes sequence
starting at the hs3 enhancer and ending at the hs1.2 enhancer (including the intervening
sequence between those enhancers) and contains the VH promoter is named pVH.hs31.2 (Fig 11). If that plasmid contains the intronic ε promoter instead, it is named pIε.hs31.2. A plasmid that contains just the hs4 enhancer and the V H promoter is named
pVH.hs4. Finally, a plasmid that contains the intronic γ3 promoter, the hs4 enhancer, and
the entire sequence from hs3 to hs1.2 is named pγ3.hs3-1.2.4. Generally speaking, a
dash between the enhancers means the sequence between the enhancers is included in
the plasmid, but a period separating the enhancers means there is no intervening
sequence between them.

The human 3’IghRR reporters pVH.hs3-1.2 and pVH.hs3-1.2.4 fail to respond to B-cell
stimulation or TCDD
The human 3’IghRR plasmids containing the intervening sequence between hs3
and hs1.2 failed to respond to B-cell stimulation or TCDD. It was expected that B-cell
stimulation would increase the activity of the enhancers since B-cell stimulation is
known to increase the transcriptional activity of the IGH gene, which is at least partially
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driven by the 3’IghRR. TCDD treatment was expected to result in reduced activity of the
plasmids since TCDD is known to act as an immunosuppressant in both mouse and
human B cells. However, when these plasmids were transfected into the human B cell
line CL-01 and stimulated by either CD40L+IL-4 or by the TLR7/8 agonist R848 the
reporters exhibited only a modest, but highly variable and statistically insignificant
change in activity (Fig. 12 and (Alfaheeda, 2016)). Similarly, treatment of the transfected
cells with TCDD, either in the stimulated or unstimulated state, also resulted in only a
modest but not statistically significant response (Fig 12. and (Alfaheeda, 2016)).
Variations in incubation time and treatment concentrations did not alter these trends.
The VH promoter in these plasmids was removed and the intronic ε and γ 3 promoters
were inserted instead. Since class switch recombination involves transcription driven by
the intronic promoters, and the 3’IghRR helps drive that transcription, it was thought
some difference in activity might be observed. A promoter was chosen from each of the
two clusters of constant regions in case their positions are functionally relevant.
Unfortunately, the results did not change regardless of the promoter used in the
plasmid (Fig. 12 and (Alfaheeda, 2016)).

The human 3’IghRR reporter pVH.hs4 fails to respond to B-cell stimulation but does
respond to TCDD
In contrast to the reporters containing large sections of the 3’IghRR sequence,
the pVH.hs4 reporter plasmid does respond to TCDD (Fig. 12 and (Alfaheeda, 2016)).
Treatment of transfected CL-01 human B cells with TCDD slightly reduces activity of the
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reporter. This result stands in stark contrast to a reporter containing the hs1.2 enhancer
alone, which increased in activity with treatment of TCDD (Fernando et al., 2012;
Freiwan, 2014). The conflicting outcomes between reporters containing either the hs1.2
enhancer or the hs4 enhancer might partially explain why the pV H.hs3-1.2.4 plasmid did
not respond to TCDD at all. However, the hs4 enhancer alone also failed to respond to
B-cell stimulation, so the failure of the larger reporters to respond as predicted to either
treatment probably cannot be explained entirely by the addition of hs4.

The human 3’IghRR reporter plasmids behave differently when transfected into human
vs mouse B cells
It has been well established that reporter plasmids containing the mouse 3’IghRR
enhancers will, for the most part, exhibit exactly the type of activity one would expect
when transfected into mouse cells and stimulated or treated with TCDD (Sulentic &
Kaminski, 2011). That is to say, their activity increases in response to B-cell stimulation
and decreases in response to TCDD, which is consistent with effects of B-cell stimulation
and TCDD on both mouse and human B cell lines (Sulentic & Kaminski, 2011). Reporter
plasmids bearing the human 3’IghRR sequence, however, behave differently depending
on if they are transfected into mouse or human cells. Previous work has shown that a
plasmid containing just the human hs1.2 enhancer will show a decrease in activity in
response to B-cell stimulation when transfected into human cells, whereas in mouse
cells B-cell stimulation will increase its activity (Alfaheeda, 2016; Freiwan, 2014). TCDD
will actually increase the activity of the human hs1.2 enhancer in both mouse and
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human cells (Alfaheeda, 2016; Freiwan, 2014). When the human pVH.hs3-1.2.4 plasmid
is transfected into mouse cells, B-cell stimulation causes an increase in activity while
TCDD causes a decrease. However, when the same plasmid is transfected into human B
cells, it has little or no response to either treatment (Fig. 12 and (Alfaheeda, 2016)). It is
unlikely this difference can be explained by a deficiency in the cell line being used since
treatment with B-cell stimulation increases antibody secretion in CL-01 cells, and TCDD
treatment decreases it, indicating the endogenous locus functions as expected. A more
likely explanation is that some aspect of gene regulation by the human 3’IghRR is not
being captured by the human reporter plasmids, which means a method to study the
endogenous 3’IghRR is needed.
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Figure 12. Summary of transfection studies using 3’IghRR reporter plasmids. Arrows pointing up
indicate an increase in reporter activity while arrows pointing down indicate a decrease in
activity. A horizontal line indicates no significant change in activity. Mouse 3’IghRR reporters
typically show an increase in activity with B-cell stimulation and decrease in activity with TCDD
treatment, except for the hs4 reporter. Human hs1.2 reporter plasmids, however, only show an
increase in activity with B-cell stimulation when mouse B-cells are used. In human B cells, the
human reporter decreases in activity with stimulation and increases activity with TCDD
treatment. Transfection studies using the pGL3.hs3-1.2.4 (Full Length) plasmid, and its
derivatives, exhibit similar activity to the mouse reporters when used in mouse cells, but show
little change in activity when used in human B cells. For additional details about the human
reporter plasmids refer to Zahra Alfaheeda’s master’s thesis (Alfaheeda, 2016).
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IV. Specific Aim 3
Specific Aim 3 Rationale
As noted previously, there are pronounced structural differences between the
human and mouse 3’IghRR. The human 3’IghRR is duplicated in humans, but not in
mice, and the hs1.2 enhancer is polymorphic in humans but not in mice. The most
obvious starting point for studying human 3’IghRR function is to investigate the role of
the 3’IghRR duplication. Several distinct possibilities exist regarding the function of the
3’IghRR duplication: 1) both the α1 and α2 regions may be required for successful
transcription of any IGH isotype 2) the α1 and α2 regions may only regulate the
transcription of their most proximal upstream constant regions 3) the α 2 region could be
sufficient for production of any IGH isotype because the α 1 region will be lost during
class switch recombination to certain isotypes 4) the duplication of the 3’IghRR may be
an entirely redundant and unnecessary by-product of evolution where either 3’IghRR
could be sufficient for production of any IGH isotype. The first hypothesis for specific
aim 3 is that the α1 3’IghRR mediates expression of the upstream constant regions while
the second group of constant regions is controlled by the α2 3’IghRR.
There are also modest structural differences between the human α1 3’IghRR and
α2 3’IghRR, in particular in the hs1.2 enhancer. As previously described, this enhancer is
polymorphic; it contains a 53 base pair invariant sequence (IS) that can be repeated up
to four times in some individuals (Mills et al., 1997; Pinaud et al., 1997). This invariant
sequence contains several transcription factor binding sites and increased numbers of
repeats are associated with increasing enhancer activity in luciferase reporters (Denizot
et al., 2001). The IS repeats within the α1 hs1.2 enhancer have also been associated with
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human disease states, which is strong evidence that these repeats are functionally
significant (Aupetit et al., 2000; Cianci et al., 2008; Frezza et al., 2004; Frezza et al.,
2009; Frezza et al., 2007; Tolusso et al., 2009; J. Wang & Boxer, 2005). The difference
between the α1 hs1.2 and α2 hs1.2 enhancer is that the α1 hs1.2 enhancer can have one,
two, three, or four repeats of the IS, whereas the α 2 hs1.2 enhancer always contains
either three or four repeats (Mills et al., 1997; Pinaud et al., 1997). Also, the two hs1.2
enhancers are in opposite orientation with respect to each other within the 3’IghRR
when a specific polymorphism is present (Denizot et al., 2001). Because the hs1.2 IS
polymorphism does not exist in mice, all 3’IghRR functional studies performed in mice
have failed to elucidate the function of the IS polymorphism, which represents a
tremendous gap in the literature in light of the association of the polymorphism with
human diseases. Therefore, specific aim 3 will also test the hypothesis that specific
combinations of the hs1.2 IS polymorphism will correspond to B cells preferentially
expressing specific Ig isotypes.

Specific Aim 3 Results
Attempts to engineer a deletion of the α 1 3’IghRR failed
Attempts were made to delete the entire α 1 3’IghRR from the CL-01 human B cell
line using two different CRISPR vectors (Fig. 13). This system takes advantage of a
bacterial anti-virus defense mechanism which utilizes the Cas9 endonuclease to digest
invading nucleic acids (Marraffini & Sontheimer, 2010). To make use of this mechanism
in research, Cas9 has been inserted into a plasmid along with a guide RNA (gRNA) and
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Figure 13. CRISPR plasmid maps. Two CRISPR plasmids were purchased from Origene (Rockville,
MD) for use in this study. The first is a standard expression plasmid containing both the Cas9
endonuclease and the guide RNA (gRNA). This plasmid also expresses GFP. The second plasmid
is a lentiviral vector which also contains the gRNA and Cas9, but does not express GFP.
Definitions of abbreviations: U6 and CMV are promoters, AMP is an ampicillin resistance gene,
CAM is a chloramphenicol resistance gene, EF1a is a promoter, GFP is green fluorescent protein,
Ori is the origin of replication, Myc/DDK represents a Myc protein tag on the Cas9
endonuclease, 5’LTR stands for long terminal repeats and serves as a retroviral promoter, 3’ SIN
LTR stands for self-inactivating long terminal repeat and is a safety feature of many lentiviral
plasmids.
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a roughly 20 base pair targeting sequence (Mali et al., 2013). When the CRISPR plasmid
is inserted into a cell, Cas9 protein is expressed and associates with the gRNA which is
tethered to the targeting sequence (Deltcheva et al., 2011). When the targeting
sequence base pairs with cellular DNA the Cas9 enzyme is pulled into proximity of the
target site by the gRNA and creates a double-strand break (DSB) in the DNA (Deltcheva
et al., 2011; Jinek et al., 2012). This double-strand break will then be ligated by one of
two cellular processes, either non-homologous end-joining (NHEJ) or homology-directed
repair (HR) (Mali et al., 2013). Exogenous DNA can be inserted into the target site by
taking advantage of the homology directed repair machinery (Zheng et al., 2014).
Alternatively, large genetic deletions can be created by introducing two double strand
breaks via CRISPR and relying on non-homologous end joining to ligate the two breaks
thereby excising the intervening sequence (Zhang et al., 2015). Non-homologous end
joining is a highly error prone pathway which will often create small insertion or
deletion mutations (indel). In some circumstances it may be desirable to use just one
double strand break and rely on these indel mutations to disrupt small regions of the
genetic code (Mali et al., 2013). This system has been used to reliably create genetic
edits, including large deletions, in a wide array of species and cell types with a minimum
of off target effects (He et al., 2015; Hilton et al., 2015; Li et al., 2015; Mali et al., 2013;
Zhang et al., 2015; Zheng et al., 2014).
In order to make the deletion of the 3’IGHRR, a double strand break needed to
be introduced on either side of the α1 3’IghRR using two different targeting sequences,
one for the 5’ end of the region and one for the 3’ end (Table 2). This means that a cell
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would need to be double transfected with two CRISPR vectors (one containing each
targeting sequence) in order for the two double strand breaks to be induced. However,
transfection efficiency in the CL-01 cells is very low (typically less than 10%) so the
likelihood of any one cell being double transfected is also very low. Furthermore,
deletions using this method tend to occur at frequencies of anywhere from 1-20%, so
only a small population of cells would have the deletion out of an already small
population of cells that was double transfected. The results reflected this difficult
scenario as 105 clonal populations of cells transfected with the first set of CRISPR
vectors were screened by PCR and found to be negative for the deletion (data not
shown). A second set of CRISPR vectors, packaged into lentiviral particles and using the
same targeting sequences, was also used. This second set of CRISPRs resulted in 189
clones being screened by PCR and they were also all negative for the deletion (data not
shown). It is possible that the targeting sequences used for this attempted deletion
were insufficient, but it could also be possible that low transfection/transduction
efficiency was also a contributing factor. It might still be possible to make this deletion
using different targeting sequences or by using two CRISPR vectors expressing different
colored fluorescent proteins (for example, GFP and Texas Red) which would allow for
sorting based on expression of both colors. For additional details on how this deletion
was attempted refer to “Materials and Methods” of this dissertation.

The hs1.2 polymorphism was successfully edited using CRISPR

39

In contrast to the attempt at deleting the α 1 3’IghRR, editing the hs1.2
polymorphism using CRISPR worked with a surprisingly high rate of success. Because the
hs1.2 polymorphism is a repeat of roughly 53 base pairs, it can be targeted multiple
times with a single CRISPR vector, eliminating the need for a double transfection (Fig. 14
and 15). A CRISPR vector that targets the hs1.2 polymorphism and induces a double
strand break in the NF1 transcription factor binding site resulted in positive edits in
roughly 20% of the cells transfected with the CRISPR plasmid. A separate CRISPR plasmid
that induced double strand breaks in the DRE binding site resulted in positive edits
roughly 15% of the time. Using this method it was possible to create clonal cell
populations which represent most of the possible combinations of the hs1.2
polymorphism (Fig. 16). Once these cell populations were derived they were examined
for differences in antibody expression compared to unedited (wild type) CL-01 cells.
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Figure 14. The α 1 hs1.2 enhancer targeted by CRISPR gene editing. The α 1 hs1.2 enhancer can be
targeted twice by the same CRISPR targeting sequence that binds the α 2 hs1.2 due to the
repetitive nature of the hs1.2 polymorphism. When the targeting sequence base pairs with the
gene the Cas9 endonuclease induces a double strand break (DSB). The two DSBs can be ligated
without the intervening sequence, effectively deleting an IS repeat, thus the α 1 hs1.2 enhancer
can go from two repeats of the IS to one.
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Figure 15. The α 2 hs1.2 enhancer targeted by CRISPR gene editing. The α 2 hs1.2 enhancer can be
targeted three times by the same CRISPR targeting sequence that binds the α 1 hs1.2 due to the
repetitive nature of the hs1.2 polymorphism. Due to some non-conserved sequence in the first
IS, the α 2 hs1.2 in the CL-01 cells cannot be targeted four times in spite of containing four IS
repeats. When the targeting sequence base pairs with the gene the Cas9 endonuclease induces
a double strand break (DSB). The three DSBs can be ligated without one or both of the
intervening sequences, thus the α 2 hs1.2 polymorphism can be reduced from four repeats to
either three or two.
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Figure 16. Genotyping the hs1.2 enhancer. Due to complete sequence homology between the α 1
hs1.2 and α 2 hs1.2 enhancers outside of the polymorphism, a single pair of PCR primers can be
used to amplify both enhancers at the same time. Predicted product sizes are 374 bp for four IS
repeats, 319 bp for three IS repeats, 264 bp for two repeats, and 209 bp for one IS. Wild type
(WT) CL-01 cells show PCR products consistent with four IS repeats in the α 2 hs1.2 and two
repeats in the α 1 hs1.2 enhancer. Clonal cell populations bearing numerous different
combinations of the hs1.2 polymorphism were generated. Clone 1-C3 was lost due to user error,
and clone 4-B8 has not been fully analyzed, so they are not included in this functional analysis.
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Clone 1-D3 has three repeats of the IS in the α2 hs1.2 and two repeats in the α1 hs1.2
Based on PCR results that amplify both of the hs1.2 enhancers, clone 1-D3 has
three repeats of the hs1.2 polymorphism in the α2 hs1.2 enhancer and two repeats in
the α1 hs1.2. Cells were analyzed after stimulation with CD40 ligand and IL-4 followed by
96 hours of incubation. Analysis of secreted IgM by ELISA reveals that IgM secretion in
this clone is unaffected by the change within the α2 hs1.2 enhancer whereas IgG
secretion is significantly reduced in both naïve and stimulated cells compared to wild
type CL-01 cells (Fig. 17). Real time PCR analysis of Ig transcripts in clone 1-D3
stimulated with CD40L and IL-4 compared to stimulated wild type cells shows a slight
increase in transcripts in most Ig isotypes, except γ 4 transcripts which are six fold higher
in 1-D3 than in wild type cells. Since this large increase in γ4 transcripts is not reflected
in the secreted IgG ELISA data it is likely the increase in γ 4 transcripts is due to an
increase in sterile germline transcripts. The α1 and α2 transcript levels are unchanged
compared to wild type cells.
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Figure 17. IGH expression in hs1.2-edited clone 1-D3. Wild type (WT) cells and clone 1-D3 were
stimulated with CD40L (6.25 ng/ml) and IL-4 (25 ng/ml) and secreted IgM (A) and IgG (B) were
measured by ELISA. Transcription of the Ig constant regions were measured by real time PCR in
stimulated cells and represented here in terms of fold change over stimulated WT cells (C). The
genotype of the hs1.2 enhancers (D) in the modified clone versus wild type CL-01 cells
demonstrates successful genetic editing. Due to complete sequence homology between the α 1
hs1.2 and α 2 hs1.2 enhancers outside of the polymorphism, a single pair of PCR primers can be
used to amplify both enhancers at the same time. Predicted product sizes are 374 bp for four IS
repeats, 319 bp for three IS repeats, 264 bp for two repeats, and 209 bp for one IS. Comparisons
between treatment groups were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post-test. One, two, or three asterisks (*) denote significance compared to
the corresponding control at p<0.05, p<0.01, or p<0.001 respectively.

45

Clone 1-A6 appears to have the same combination of hs1.2 IS repeats as WT cells but
expresses Ig isotypes differently
Clone 1-A6 appears to have four IS repeats in the α 2 hs1.2 enhancer and two IS
repeats in the α1 hs1.2 enhancer just like the WT cells. However, this clone behaves
quite differently than WT cells (Fig. 18). Clone 1-A6 shows a modest reduction in
secreted IgM and a large reduction in the amount of secreted IgG being expressed
compared to WT cells. However, comparing the amount of γ transcripts of all subtypes
in stimulated 1-A6 compared to stimulated WT cells reveals very little difference. The
most significant change in transcript levels is in the two α subtypes and ε transcripts.
Both the α1 and α2 isotypes show a significant reduction in transcript levels whereas the
ε transcripts are 3.5 fold higher in clone 1-A6 than in WT cells. So, how can clone 1-A6
be expressing Ig differently than WT cells when they have the same genotype? The most
likely explanation is that clone 1-A6 experienced a small insertion or deletion (indel)
mutation when the CRISPR-induced double stand breaks were ligated through nonhomologous end joining (Fig. 19). If this is true, it means all the differences Ig expression
observed with this clone are the result of a disruption in the NF1 transcription factor
binding site. Attempts to verify this hypothesis by sequencing the genotyping PCR
products have so far met with limited success. One reliable sequence was generated for
each product, but the sequence was identical to wild type cells. This does not mean 1A6 is a wild type cell,
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Figure 18. IGH expression in hs1.2-edited clone 1-A6. Wild type (WT) cells and clone 1-A6 were
stimulated with CD40L (6.25 ng/ml) and IL-4 (25 ng/ml) and secreted IgM (A) and IgG (B) were
measured by ELISA. Transcription of the Ig constant regions were measured by real time PCR in
stimulated cells and represented here in terms of fold change over stimulated WT cells (C). The
genotype of the hs1.2 enhancers (D) in the modified clone versus wild type CL-01 cells appears
identical on an agarose gel even though the clone has a different Ig expression profile. Due to
complete sequence homology between the α 1 hs1.2 and α 2 hs1.2 enhancers outside of the
polymorphism, a single pair of PCR primers can be used to amplify both enhancers at the same
time. Predicted product sizes are 374 bp for four IS repeats, 319 bp for three IS repeats, 264 bp
for two repeats, and 209 bp for one IS. Comparisons between treatment groups were analyzed
using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post-test. One, two, or
three asterisks (*) denote significance compared to the corresponding control at p<0.05, p<0.01,
or p<0.001 respectively.
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Figure 19. Non-homologous end joining (NHEJ) and lead to insertion/deletion (indel) mutations.
If the CRISPR-induced double strand break is repaired by NHEJ a random number of nucleotides
can be inserted or deleted from the DNA sequence because NHEJ is an error prone pathway.
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however, because the sequencing data might represent only one allele due to the
sequencing method employed. The other allele might have a mutation. But since it is
currently unknown which allele was successfully sequenced (it could have been either
the functional or translocated allele) it’s impossible to precisely define the genotype of
clone 1-A6.

Clones 1-B5 and 4-E10 have four IS repeats in the α2 hs1.2 enhancer and one IS in the α1
hs1.2
Although they have different genotypes clone 1-B5 behaves very similarly to
clone 1-A6 in terms of Ig expression (Fig. 20). This clone has very slightly reduced
expression of secreted IgM but dramatically reduced expression of secreted IgG. All four
of the γ subtypes are showing elevated transcript levels, with roughly a 2 fold increase
over WT cells. Similar to clone 1-A6, both α subtypes are reduced compared to WT cells,
whereas the ε transcripts are 6 fold higher in the modified clone than in WT cells. The
similarity in expression patterns between 1-A6 and 1-B5 might indicate that an indel
mutation occurred in the α1 hs1.2 enhancer of clone 1-A6 that disrupted a transcription
factor binding site essential for normal expression of α and ε transcripts. It would be
expected that a clone with the same genotype as 1-B5 would have the same pattern of
Ig expression, but clone 4-E10 expressed Ig isotypes differently than 1-B5 despite having
the same genotype (Fig. 21). Secreted IgM and IgG are expressed in a similar way in 4E10 as in 1-B5, namely, both isotypes are secreted at lower levels than in WT cells.
However, transcript levels in stimulated 4-E10 are not significantly different than in
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Figure 20. IGH expression in hs1.2-edited clone 1-B5. Wild type (WT) cells and clone 1-B5 were
stimulated with CD40L (6.25 ng/ml) and IL-4 (25 ng/ml) and secreted IgM (A) and IgG (B) were
measured by ELISA. Transcription of the Ig constant regions were measured by real time PCR in
stimulated cells and represented here in terms of fold change over stimulated WT cells (C). The
genotype of the hs1.2 enhancers (D) in the modified clone versus wild type CL-01 cells
demonstrates successful genetic editing. Due to complete sequence homology between the α 1
hs1.2 and α 2 hs1.2 enhancers outside of the polymorphism, a single pair of PCR primers can be
used to amplify both enhancers at the same time. Predicted product sizes are 374 bp for four IS
repeats, 319 bp for three IS repeats, 264 bp for two repeats, and 209 bp for one IS. Comparisons
between treatment groups were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post-test. One, two, or three asterisks (*) denote significance compared to
the corresponding control at p<0.05, p<0.01, or p<0.001 respectively.
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Figure 21. IGH expression in hs1.2-edited clone 4-E10. Wild type (WT) cells and clone 4-E10 were
stimulated with CD40L (6.25 ng/ml) and IL-4 (25 ng/ml) and secreted IgM (A) and IgG (B) were
measured by ELISA. Transcription of the Ig constant regions were measured by real time PCR in
stimulated cells and represented here in terms of fold change over stimulated WT cells (C). The
genotype of the hs1.2 enhancers (D) in the modified clone versus wild type CL-01 cells
demonstrates successful genetic editing. Due to complete sequence homology between the α 1
hs1.2 and α 2 hs1.2 enhancers outside of the polymorphism, a single pair of PCR primers can be
used to amplify both enhancers at the same time. Predicted product sizes are 374 bp for four IS
repeats, 319 bp for three IS repeats, 264 bp for two repeats, and 209 bp for one IS. Comparisons
between treatment groups were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post-test. One, two, or three asterisks (*) denote significance compared to
the corresponding control at p<0.05, p<0.01, or p<0.001 respectively.
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stimulated WTcells for all Ig isotypes except for γ 2 transcripts. The difference in Ig
expression patterns between 4-E10 and 1-B5, despite them both having the same
genotype, could be due to the presence of small indel mutations that are undetectable
on an agarose gel. Thorough sequencing of both clones will be necessary to determine if
significant genetic differences exist between the clones that might explain these
differences.

Clone 2-F11 has a genotype that was not predicted
Clone 2-F11 is unusual because it shows a genotype that was not predicted prior
to the isolation of clonal populations transfected with the CRISPR plasmid. The
genotyping PCR produces a band that runs halfway between the expected sizes of a two
IS repeat and three IS repeat of the hs1.2 enhancer (Fig. 16 and 22). A second band runs
at roughly the predicted size for one IS. The genotyping PCR typically produces a much
thicker, darker band for this clone than for any of the other clones and it is always the
abnormally sized band that is darker. Attempts to sequence that PCR product have so
far been unsuccessful. Clone 2-F11 produces secreted IgM at roughly equivalent levels
as WT cells (Fig. 22). Secreted IgG in naïve 2-F11 cells and WT cells are very similar, but
secreted IgG levels do not increase with stimulation as much for 2-F11 as they do for
stimulated WT cells. This stands in stark contrast to γ transcripts, which are all elevated
in stimulated 2-F11 compared to stimulated WT cells. This probably reflects an increase
in germline transcription in 2-F11. Transcripts of ε are elevated by roughly 2 fold over
WT cells, whereas transcription of both α subtypes is reduced.
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Figure 22. IGH expression in hs1.2-edited clone 2-F11. Wild type (WT) cells and clone 2-F11 were
stimulated with CD40L (6.25 ng/ml) and IL-4 (25 ng/ml) and secreted IgM (A) and IgG (B) were
measured by ELISA. Transcription of the Ig constant regions were measured by real time PCR in
stimulated cells and represented here in terms of fold change over stimulated WT cells (C). The
genotype of the hs1.2 enhancers (D) in the modified clone versus wild type CL-01 cells
demonstrates successful genetic editing. Due to complete sequence homology between the α 1
hs1.2 and α 2 hs1.2 enhancers outside of the polymorphism, a single pair of PCR primers can be
used to amplify both enhancers at the same time. Predicted product sizes are 374 bp for four IS
repeats, 319 bp for three IS repeats, 264 bp for two repeats, and 209 bp for one IS. Comparisons
between treatment groups were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post-test. One, two, or three asterisks (*) denote significance compared to
the corresponding control at p<0.05, p<0.01, or p<0.001 respectively.
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Both of the hs1.2 enhancers have been edited in clone 4-D5
Clone 4-D5 is the only clone produced that has had both of the hs1.2 enhancers
edited. All of the other clones have at least one enhancer that appears to be unedited,
although small indel mutations cannot be ruled out at this time. Clone 4-D5 has three IS
repeats in the α2 hs1.2 enhancer and one IS in the α1 hs1.2. This clone exhibits a
significant reduction in secreted IgM as well as IgG (Fig. 23). It’s also the only clone in
which transcripts for all the Ig isotypes are expressed at lower levels than WT when the
cells are stimulated. The α1 and γ2 transcripts see the biggest reductions compared to
WT cells while γ1 and ε transcripts are more modestly reduced.

The α1 hs1.2 enhancer appears to have been entirely deleted in clone 2-F3
Clone 2-F3 is unique in that it appears to have the entire α1 hs1.2 deleted based
on the results of the genotyping PCR (Fig. 16 and 24). The α2 hs1.2 appears to be
unedited in this clone. When a double strand break is repaired by the homology
directed repair mechanism in the absence of donor DNA with homologous sequence
near the break a 5’ resection can occur that results in some portion of the genome being
deleted (Fig. 25) (Paudyal & You, 2016). It is likely this mechanism has deleted some
portion of the α1 hs1.2 enhancer, but it is unknown how much sequence was lost.
Interestingly, despite the apparent loss of the α1 hs1.2 enhancer, secreted IgM and IgG
appear to have been mostly unaffected by this genetic edit (Fig. 24). Examination of Ig
transcripts, however, reveals that several of the Ig isotypes are being transcribed at
lower levels in stimulated 2-F3 then in stimulated WT cells. Of special significance is a
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large reduction in ε transcription which suggests the α1 hs1.2 enhancer is surprisingly
important in the expression of the downstream cluster of constant regions.
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Figure 23. IGH expression in hs1.2-edited clone 4-D5. Wild type (WT) cells and clone 4-D5 were
stimulated with CD40L (6.25 ng/ml) and IL-4 (25 ng/ml) and secreted IgM (A) and IgG (B) were
measured by ELISA. Transcription of the Ig constant regions were measured by real time PCR in
stimulated cells and represented here in terms of fold change over stimulated WT cells (C). The
genotype of the hs1.2 enhancers (D) in the modified clone versus wild type CL-01 cells
demonstrates successful genetic editing. Due to complete sequence homology between the α 1
hs1.2 and α 2 hs1.2 enhancers outside of the polymorphism, a single pair of PCR primers can be
used to amplify both enhancers at the same time. Predicted product sizes are 374 bp for four IS
repeats, 319 bp for three IS repeats, 264 bp for two repeats, and 209 bp for one IS. Comparisons
between treatment groups were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post-test. One, two, or three asterisks (*) denote significance compared to
the corresponding control at p<0.05, p<0.01, or p<0.001 respectively.
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Figure 24. IGH expression in hs1.2-edited clone 2-F3. Wild type (WT) cells and clone 2-F3 were
stimulated with CD40L (6.25 ng/ml) and IL-4 (25 ng/ml) and secreted IgM (A) and IgG (B) were
measured by ELISA. Transcription of the Ig constant regions were measured by real time PCR in
stimulated cells and represented here in terms of fold change over stimulated WT cells (C). The
genotype of the hs1.2 enhancers (D) in the modified clone versus wild type CL-01 cells
demonstrates successful genetic editing. Due to complete sequence homology between the α 1
hs1.2 and α 2 hs1.2 enhancers outside of the polymorphism, a single pair of PCR primers can be
used to amplify both enhancers at the same time. Predicted product sizes are 374 bp for four IS
repeats, 319 bp for three IS repeats, 264 bp for two repeats, and 209 bp for one IS. Comparisons
between treatment groups were analyzed using a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post-test. One, two, or three asterisks (*) denote significance compared to
the corresponding control at p<0.05, p<0.01, or p<0.001 respectively.
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Figure 25. 5’ resections can lead to large genomic deletions. If a cell attempts to repair a CRISPRinduced double strand break using the homology directed repair mechanism without
homologous donor DNA present, a 5’ resection can occur. When this happens, the 5’ end of the
double strand break is degraded until enough homologous DNA is found on the 3’ overhang for
homology directed repair to seal the break.
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V. Discussion
Our previous work has shown the mouse 3’ IghRR to be a sensitive target of
TCDD, and further work with an AhR antagonist or shRNA knockdown of the AhR
strongly support an AhR-mediated mechanism for the effects of TCDD (Sulentic et al.,
1998, 2000; Sulentic et al., 2004; Wourms & Sulentic, 2015). However, it is unknown
exactly where in the human 3’ IGHRR AhR might be binding or if instead of directly
binding to DNA AhR might be interacting with, or altering expression of, other
transcription factors that bind to the 3’ IGHRR. Out of the three enhancers found in the
human 3’IghRR, the hs1.2 enhancer has the highest density of transcription factor
binding sites, and is the only one known to be polymorphic in the human population
(Sulentic & Kaminski, 2011). All four versions of the polymorphic hs1.2 enhancer are
sensitive targets of TCDD, and therefore could be sensitive to other exogenous AhR
ligands, making the hs1.2 enhancer a potential target of immunotherapies. These
polymorphisms have been associated with a variety of immunological disorders
including lupus erythematosus, dermtatis herpatiformis, plaque psoriasis, psoriatic
arthritis, rheumatoid arthritis, systemic scerlosis, coeliac disease, IgA deficiency, IgA
nephropathy, and even schizophrenia and AIDS progression so the hs1.2 enhancer is of
particular interest to human health (Aupetit et al., 2000; Cianci et al., 2008; Frezza et al.,
2004; Frezza et al., 2009; Frezza et al., 2007; Frezza et al., 2012; Giambra et al., 2009;
Montesano et al., 2014; Tolusso et al., 2009). Therefore, one goal of this project was to
evaluate the individual contributions of each transcription factor binding site to hs1.2
enhancer activity.
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Assessing the role of the AP1.Ets binding site through site-directed mutagenesis
of the hs1.2 luciferase reporter has revealed this site to be a strong regulator of overall
hs1.2 enhancer activity. In stark contrast to every other binding site mutation assessed
in this study, the AP1.Ets site is the only one that reduced activity of the hs1.2 enhancer.
This result suggests the AP1.Ets site is a strong positive regulator of hs1.2 enhancer
activity. Other studies have shown c-Jun and c-fos to be the transcription factors that
bind to this enhancer, but it would be useful to know if any other proteins could bind to
this site (Sulentic & Kaminski, 2011). Because the hs1.2 enhancer is associated with so
many human diseases, and because the AP1.Ets site has now been shown to be a strong
regulator of hs1.2 enhancer activity, a possibility exists that this binding site could be a
therapeutic target. For example, in lymphoma patients with chromosomal
translocations of the 3’ IGHRR to proto-oncogenes (i.e. c-myc, bcl-2, ect), blocking this
site might significantly reduce the potential oncogenic effect of the translocation.
Like the AP1.Ets site the transcription factor, octamer is located 5’ of the
invariant sequence. Oct contributes to mouse hs1.2 enhancer activity and is conserved
between mouse and human (Mills et al., 1997). In B cells, Oct in collaboration with Grich, κB-like motifs and Pax5 repress transcription of the murine hs1.2 enhancer (Singh
& Birshtein, 1996). Our mutation of the Oct binding site in the human hs1.2 enhancer
suggests a conservation of function in the human locus, since mutating the Oct binding
site lead to an increase in overall luciferase activity. Furthermore, an Oct binding motif is
frequently present in AhR-sensitive genes, suggesting a potential role in AhR signaling
and TCDD-induced modulation (Kel et al., 2004). In the current study, mutation of the
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Oct binding site in the hs1.2 reporter plasmid significantly increased TCDD-induced
activation in unstimulated B cells. Under these conditions, Oct must act as an inhibitor
of TCDD-induced activity. However, this effect was not observed in LPS-stimulated B
cells, perhaps some aspect of TLR-4 signaling masks or eliminates the inhibitory effect of
Oct on TCDD-induced hs1.2 activation. Additionally, cellular stimulation increases AhR
expression (Sulentic et al., 2000), so perhaps the additional AhR protein can compensate
for the inhibitory effect of Oct (C. F. Vogel et al., 2014). Another possibility is that TLR-4
signaling can lead to increased expression of transcription factors that target the hs1.2
enhancer, such as NF-κB and AP-1, and these proteins could be overriding an inhibitory
role of Oct in TCDD-induced activation when B cells are stimulated (C. F. Vogel et al.,
2014).
A number of studies have reported a TCDD-induced influence on AP-1, but
outcomes vary on whether the transcription factor’s activity increases or decreases. In
LPS-activated CH12.LX cells, one study showed that TCDD up-regulated AP-1 binding
within the promoter of B lymphocyte–induced maturation protein-1 (Blimp-1), a critical
regulator of B-cell differentiation and a negative transcriptional repressor of Pax5
(Schneider, Manzan, Yoo, Crawford, & Kaminski, 2009). In this same study a link was
made between TCDD-mediated suppression of Blimp-1 through AP-1 binding and Pax5
dysregulation (Schneider et al., 2009). Also, other studies conducted in multiple liver cell
types showed an increase in AP-1 DNA binding activity resulting from genes induced by
AhR agonists (Ashida, Nagy, & Matsumura, 2000; Puga, Nebert, & Carrier, 1992). In
opposition Suh and colleagues demonstrated that TCDD inhibited DNA binding and
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transcriptional activity of AP-1 in LPS-activated CH12.LX cells (Suh et al., 2002). In the
same study TCDD was unable to inhibit AP-1 activity in an AhR- deficient murine B cell
line, BCL-1 (Suh et al., 2002). Even though TCDD-induced effects on AP-1 differ, it is clear
that AP-1 effected by TCDD. In this study, no significant effect on TCDD-induced activity
of the human hs1.2 enhancer was observed, although the α 1AAP1mut resulted in
significantly higher transcription by the enhancer in both unstimulated and LPSstimulated CH12.LX cells. The AP-1 site seems to play an inhibitory role in the overall
transcription of the human hs1.2 enhancer, but doesn’t appear to play a role in TCDDinduced modulation, a surprising result in the context of the previous work. If TCDD
truly inhibits AP-1 binding in CH12.LX cells, our reporter system would not likely detect a
TCDD effect on the already mutated AP-1 binding site, so this study does not rule out
the possibility of a TCDD/AhR-AP-1 interaction.
Like the IS AP-1 site, TCDD-induced modulation of the human polymorphic hs1.2
enhancer was thought to involve the IS NF-κB site. NF-κB activity contributes to the
activation of mouse hs1.2 enhancer at the plasma cell stage (Michaelson et al., 1996).
Also, NF-κB has been found to modulate AhR signaling, which may explain how TCDDinduced immunotoxicity is mediated (Tian, 2009; C. F. Vogel et al., 2014). Transcriptional
activity of the AhR and NF-κB has been shown to be regulated by the same corepressors and co-activators, such as steroid receptor coactivator-1 (SRC-1) and
p300/CBP (Tian, 2009). Because co-regulators are required for both pathways, it is
possible that competition for binding occurs causing one pathway to be active while the
other pathway is suppressed (Tian, 2009). Once again, the results of our mutational
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analysis indicate that binding of the NF-kB transcription factor to its putative binding site
does not affect TCDD-induced activity of the hs1.2 enhancer. However, transient
transfections of CH12.LX cells resulted in significantly higher transcriptional activity from
mutation of the NF-κB site in both unstimulated and LPS-stimulated cells.
This mutational analysis of the human hs1.2 enhancer’s transcription factor
binding sites has yielded some surprising results. The DRE is often assumed to be a
binding site of the AhR due to work in the CYP1A1 locus and this was thought to be the
case in the hs1.2 enhancer as well (reviewed in (Beischlag, Luis Morales, Hollingshead, &
Perdew, 2008; Hanieh, 2014; Quintana, 2013)). In fact, our previous work has shown
that AhR binds to the DRE in the mouse hs1.2 enhancer (Salisbury & Sulentic, 2015;
Sulentic et al., 1998, 2000; Sulentic et al., 2004). However, the results of our mutational
analysis suggest that either the AhR is not binding to the DRE in the human hs1.2 or that
such binding is unnecessary for AhR-mediated induction of hs1.2 activity. Instead, the
nuclear factor 1 transcription factor binding site appears to be a much more important
regulator of TCDD-induced activity of the hs1.2 enhancer. It is not immediately clear
why this might be the case. Perhaps the AhR is binding to NF1 through protein-protein
interactions rather than binding directly to the DNA. There is evidence in the literature
to suggest that the AhR can bind directly to other transcription factors (Kobayashi et al.,
1996; Tian, 2009; F. Wang et al., 1999), but so far no one has shown a direct interaction
between AhR and NF1. Another possibility could be a cooperative interaction involving
AhR, NF1, SP-1, Oct, and NF-kB since AhR binding to SP-1 and NF-kB has been
demonstrated previously as well as an interaction between NF1 and SP-1 (Kobayashi et
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al., 1996; Sepulveda, Emelyanov, & Birshtein, 2004; Tian, 2009; C. F. Vogel et al., 2014; F.
Wang et al., 1999). A complicating factor is that our NF1 binding site mutation only
showed reduced TCDD-induced activity when the cells were stimulated with LPS. This
suggests that some aspect of TLR-4 signaling or B-cell stimulation is required. The
specific mechanism that triggers this potential association is unknown, but it might be
related to the increased expression of AhR following LPS stimulation (C. F. Vogel et al.,
2014). Furthermore, since mutation of the NF1 binding site only reduces, but does not
eliminate TCDD-induced activation of the hs1.2 enhancer there must be an additional
unknown mechanism at work. Regardless, the results of this study indicate that TCDDinduced activity of the hs1.2 enhancer occurs through a non-canonical AhR mediated
pathway involving Oct and NF1.
This is the first study to attempt to understand the individual contributions of
each transcription factor binding site within the hs1.2 enhancer of the 3’ IghRR.
Understanding the regulatory framework which modulates IgH expression is vital to
finding new treatments for immunological diseases and the pathologies associated with
exogenous chemicals that affect the immune system. Our findings indicate the hs1.2
enhancer is subject to a complex regulatory scheme involving many transcription factors
that might bind directly to the enhancer itself or alter activity by binding to each other.
Different types of B-cell stimulation are likely to play a key role in how these
transcription factors carry out their functions since different stimulatory pathways will
likely result in a slightly different mix of factors playing out their roles within the hs1.2
enhancer. Further studies involving additional types of B-cell stimulation are needed to
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fully understand when and why each transcription factor binding site comes into play.
Furthermore, the hs1.2 enhancer might interact with the IgH intronic promoters as well
as the VH promoter, so our study might have missed significant effects of some
mutations, especially if certain hs1.2 transcription factors only function in the context of
specific promoters. Therefore, future studies should also be performed using alternative
promoters. However, this study provides a rough outline of the relative effect of each
transcription factor binding site within the hs1.2 enhancer, which is a significant first
step in understanding the complexity of IgH regulation.
As work was underway to understand the activity of the human hs1.2 enhancer
something strange was noticed about the activity of the human hs1.2 reporter plasmid.
When the human hs1.2 enhancer was transfected into human B cells, which were then
stimulated by CD40L and IL-4 (or other types of stimulation) the activity of the plasmid
goes down compared to unstimulated cells. This response to stimulation is the opposite
of what was expected and it is the opposite of what the mouse hs1.2 reporter does in
mouse B cells. When a B cell is subject to stimulation the 3’IghRR is expected to drive an
increasing amount of Ig expression so reporter plasmids containing elements of the
3’IghRR would also be expected to increase their activity in response to B-cell
stimulation. These expectations have been reinforced by numerous reporter plasmid
studies using elements of the mouse 3’IghRR. So, the fact that the human hs1.2 reporter
plasmid decreases in activity when transfected into stimulated human B cells was an
unexpected and puzzling finding. The picture was further complicated when it was
noticed that transfecting mouse B cells with the human hs1.2 reporter plasmid results in
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an increase in activity with B-cell stimulation, just as was expected with human cells.
Unfortunately, treating cells with TCDD after transfection with the human hs1.2
reporter resulted in further confusion.
Since TCDD is known for its immunosuppressive effects in animal models it was
expected that treating human B cells with TCDD would result in lower expression of Ig,
which is exactly what happens in the CL-01 human B cell line when secreted IgG is
measured by ELISA. Logically, the human hs1.2 reporter plasmid would be expected to
show a decrease in activity when transfected into human B cells treated with TCDD
since the hs1.2 enhancer is thought to be partially driving transcription in the
endogenous locus. However, the opposite is observed. Treating either human or mouse
B cells with TCDD and transfecting them with the human hs1.2 reporter plasmid results
in an increase in activity. In contrast, the mouse hs1.2 reporter plasmid does show the
expected decrease in activity when transfected into mouse B cells and treated with
TCDD. Taken together, the surprising results from transfection studies using the human
hs1.2 reporter plasmid, and its unexpected response to B-cell stimulation and TCDD,
suggests that some essential aspect of 3’IghRR activity is being missed when the human
hs1.2 enhancer is studied in isolation. It’s possible that removing the human hs1.2
enhancer from the context of the endogenous 3’IghRR results some alteration to the
way in which its activity would normally be regulated. Therefore, putting the human
hs1.2 enhancer back into a more natural context, with additional elements of the
3’IghRR, might restore the activity of the human reporter plasmid to something more
closely resembling results from the mouse reporter studies.
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With all of this in mind, a new human 3’IghRR reporter plasmid has been
constructed that includes more of the 3’IghRR sequence to put the hs1.2 enhancer into
a context more similar to the endogenous locus. The new reporter includes sequence
that starts just 5’ of the hs3 enhancer and runs all the way through the hs1.2 enhancer,
including all the sequence between these two enhancers. It has long been thought that
the sequence between the enhancers of the 3’IghRR has some functional significance.
The intervening sequences include long stretches of nucleotide repeats, which might be
considered microsatellite repeats, and are thought to contribute to the formation of
secondary structures in the 3’IghRR. Recent work using knock out mice in which these
sequences were deleted revealed a steep decrease in Ig expression in their absence
(Garot et al., 2016). By including the 5 kb of sequence between hs3 and hs1.2 it was
hoped that some of these secondary structures might be preserved in the new reporter
plasmid. Unfortunately, due to the technical difficulty involved the roughly 15 kb of
sequence between hs1.2 and hs4 could not also be included in the reporter. Additional
nucleotide repeats are present in that portion of the sequence, which means that
essential secondary structures could still be missed in studies using the new reporter.
Another interesting feature of the intervening sequence between the 3’IghRR enhancers
is the presence of many potential nuclear factor binding sites. These sites match the
consensus binding sequence for AP-1 and DRE, but it’s not known if these sites are
functional or not. There are three potential AP-1 sites and three potential DRE sites in
the sequence between hs3 and hs1.2, which was included in the new plasmid.
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Additional potential binding sites are present in the sequence between hs1.2 and hs4,
which was not included in the plasmid.
Several different versions of the new 3’IghRR reporter plasmid have been
constructed. One version of the plasmid (pV H.hs3-1.2) includes the sequence from hs3
all the way to hs1.2 but does not include the hs4 enhancer. A second version of the
plasmid (pVH.hs3-1.2.4) is identical to the first but has the hs4 enhancer ligated to the 3’
end of the hs1.2 enhancer. Both of these versions of the plasmid are under the control
of the variable heavy chain promoter (V H). It’s thought that the 3’IghRR can also interact
with the Ig heavy chain intronic promoters. These promoters sit 5’ of each Ig constant
region and become active during class switch recombination. They drive the
transcription of sterile, germline transcripts which are not translated into protein (Ju et
al., 2011; Ju et al., 2007). Since one possible explanation for the unexpected outcomes
with the human hs1,2 reporter plasmid could be the use of the V H promoter rather than
an intronic promoter, some of these intronic promoters were included in versions of the
new reporter plasmid. The γ3 intronic promoter was included in the plasmid designated
pIγ3.hs3-1.2.4 and the ε intronic promoter was used in pIε.hs3-1.2.4. These two
promoters were chosen because it was thought there might be difference in activity
when a promoter from the upstream cluster of constant regions was used versus one
from the downstream cluster. Also, when the CL-01 cells are treated with TCDD previous
results have shown a reduction in IgG secretion. When these cells are stimulated by
CD40L and IL-4 a bona fide class switch to ε transcription can be observed, so it’s
thought that the 3’IghRR is actively engaged with these two promoters in the CL-01 cell
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line. It was hoped that some difference in activity would be observed between the three
promoters reflecting differential regulation of the isotypes by the 3’IghRR.
Results from transfection studies using the pV H.hs3-1.2 and pVH.hs3-1.2.4
plasmids in the CL-01 cells were very similar. The plasmids did not react much to either
B-cell stimulation or TCDD treatment, whereas the hs1.2 reporter reacted strongly to
both. One explanation for this could be that some portions of the 3’IghRR might have
opposing regulatory roles in human cells so adding the extra sequence could have
neutralized whatever impact on activity each of the individual elements was
contributing. This explanation seems insufficient, however, because when these new
reporters were transfected into mouse B cells their activity was similar to the original
predicted results. In mouse cells, their activity increased with stimulation and decreased
with TCDD. Perhaps the mouse and human 3’IghRRs are controlled differently. After all,
the mouse sequence contains a different complement of transcription factor binding
sites and is missing the hs1.2 polymorphism, so this might be a case where results from
the animal model simply don’t apply to the human system. If that’s true, than much of
what was assumed to be true about the human 3’IghRR could be inaccurate. A
complicating factor is that the 15 kb of sequence between hs1.2 and hs4 is missing in
these plasmids, and if that sequence is functional the results from these studies might
not reflect the activity of the endogenous locus. Unfortunately, transfection studies
utilizing versions of these plasmids under the influence of the intronic promoters
resulted in activity that was either very similar to the V H plasmids or were too
inconsistent to contribute to this analysis. These studies simply highlight the need to
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move away from reporter plasmids and begin studying the endogenous human 3’IghRR
directly. Fortunately, recent advances in gene editing technology have finally made it
possible to do so.
The development of CRISPR-mediated gene editing allows for direct study of the
human 3’IghRR for the first time. Previous genetic engineering technologies would have
been too cumbersome, expensive, or inaccurate to effectively make the targeted
genetic alterations necessary to study essential elements of the human 3’IghRR. The
extremely high degree of homology between the α 1 and α2 3’IghRRs makes it difficult to
specifically edit either one or the other, but since CRISPR only requires a 20 bp targeting
sequence it should be possible to specifically edit either 3’IghRR. There are small
stretches of DNA sequence that are specific to either the α1 or α2 3’IghRR at both the 3’
and 5’ ends of each regulatory region, which means that it should be possible to
selectively delete either the α1 or α2 3’IghRR by using CRISPR to induce a double strand
break on either side of it. This method was employed to attempt a deletion of the α 1
3’IghRR.
Since the commercially available CRISPR plasmid utilized for this project contains
only a single targeting sequence it was necessary to use two CRISPR plasmids to target
either end of the α1 3’IghRR. This was a serious problem since the CL-01 human B cell
line is resistant to most transfection techniques. Typical transfection efficiencies for this
cell line are less than 10% so the likelihood of co-transfecting any single cell with two
plasmids is very low. Furthermore, even if a cell is successfully double transfected the
success rate of creating large deletions using CRISPR can also be quite low. Never the
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less, this method was attempted to delete the entire 20 kb of sequence in the α 1
3’IghRR. After transfecting CL-01 cells with the CRISPR plasmids clonal populations were
derived by limiting dilution, DNA was extracted, and 105 clones were screened for the
deletion by PCR. All 105 clones appeared to be WT cells based on the PCR results. This
was not unexpected given the very low probabilities at play between the co-transfection
and a potentially low rate of successful deletion by CRISPR.
A second method was employed to attempt this large deletion of the α 1 3’IghRR.
Rather than using a standard expression vector for the CRISPR plasmid, lentiviral vectors
were employed. It was hoped that the CL-01 cells could be infected with a lentivirus at a
much higher rate than was possible with a standard transfection. Following infection of
the CL-01 cells and a limiting dilution 189 clonal populations were screened for the
deletion by PCR. Once again, all were WT cells. It’s possible that the rate of successfully
double infected cells, combined with the rate of successful CRISPR-mediated deletions,
was still too low to capture an edited clone. Another explanation could be that the
targeting sequences used in the CRISPR plasmids were not specific enough to make
double stand breaks at both of the required locations. Sequencing the 3’IghRR has
always been problematic due to its complexity, repetitiveness, high G-C content, and
homology between the two 3’IghRRs. So, perhaps the targeted sequence was slightly
different in the CL-01 cell line than the predicted sequence used for designing the
targets. If this experiment were repeated using additional targeting sequences at both
ends of the α1 3’IghRR, creating this knock out cell line could still be possible.
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Taking a more narrow focus, and attempting to edit the hs1.2 enhancer rather
than the entire 3’IghRR, presents a better opportunity to create genetically modified CL01 cells. In this instance, the repetitive nature of the 3’IghRR can be used to our
advantage. The polymorphic invariant sequence within the hs1.2 enhancer is of
particular interest because this polymorphism has been statistically associated with a
host of immunological diseases in humans (Aupetit et al., 2000; Cianci et al., 2008;
Frezza et al., 2004; Frezza et al., 2009; Frezza et al., 2007; Frezza et al., 2012; Giambra et
al., 2009; Tolusso et al., 2009). Since this polymorphism is composed of 53 bp of DNA
that are repeated one after another, the hs1.2 polymorphism can be targeted multiple
times with a single CRISPR plasmid. However, because the α1 and α2 hs1.2 enhancers are
nearly identical a single CRISPR plasmid will not be able to distinguish between them
and both will be targeted. The α1 hs1.2 enhancer contains two repeats of the
polymorphic IS and can be cut twice by a single CRISPR plasmid, creating an enhancer
with a single incidence of the IS. The α 2 hs1.2 enhancer has four repeats of the IS, but
because the first one is not entirely conserved the α 2 hs1.2 can only be cut three times
via CRISPR. Therefore, the α2 hs1.2 can be reduced from four repeats of the IS to either
three or two repeats. The experiment was performed using two different CRISPR
plasmids (transfected into separate pools of cells), one targeting the NF1 binding site
and the other targeting the DRE binding site. The plasmid targeting the NF1 binding site
resulted in successfully edited cells roughly 20% of the time whereas the DRE- targeting
CRISPR results in edited cells roughly 15% of the time, highlighting the need to use
multiple targeting sequences when attempting to make genetic edits using CRISPR.
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Analysis of the edited clones leaves no doubt that editing the hs1.2
polymorphism can have a severe impact on Ig expression. Every edited clone expressed
at least one Ig isotype differently than unedited WT cells. In many cases, the edited
clones expressed secreted IgM at the same level as WT cells in both stimulated and
unstimulated conditions. Several clones exhibited dramatically reduced IgG secretion
and appeared to be unable to increase IgG secretion with B-cell stimulation.
Interestingly, the only clone that had reduced transcription of every Ig isotype is also the
only clone where both the α1 and α2 hs1.2 enhancers had been edited. This could mean
that reducing the number of IS repeats in both enhancers results in decreased Ig
expression across the entire locus. That would be consistent with the theory that
transcription factor binding of the hs1.2 enhancer is the driving force behind 3’IghRR
activity. Logically then, if some of these binding sites are removed there would be lower
overall activity. However, when only one of the two hs1.2 enhancers is edited some of
the Ig isotypes are expressed at higher levels. One possibility is that it’s the ratio of
certain transcription factors bound to the enhancer that is most important to hs1.2mediated transcription. Removing one repeat from either hs1.2 enhancer but leaving
the other enhancer unedited would change the relative number of transcription factors
bound. Several of the transcription factors that bind to the hs1.2 enhancer are known to
interact with each other, either directly or indirectly, so the alteration of the ratio of
bound α1 hs1.2 transcription factors to bound α2 hs1.2 transcription factors could lead
to specific changes in activity of the enhancers by changing the availability of
transcription factors to the promoters.
73

Based on mouse studies, it is likely that the human 3’IghRR engages in long range
looping to interact with the VH promoter as well as the intronic IGH promoters (Ju et al.,
2007; Montefiori et al., 2016). As such, it is also likely that three dimensional
conformational changes to the IGH locus are highly important to overall Ig expression.
It’s possible that alterations to the hs1.2 polymorphism effect the conformation of the
locus through an interaction between the two 3’IghRRs. If the hs1.2 transcription factors
are interacting with each other, the two hs1.2 enhancers might interact with each other
as much as with the promoters. If this is the case, it would be easy to understand how a
change in the number of IS polymorphisms can have a large impact on IGH expression.
Reducing the number of available transcription factor binding sites would be like
reducing the amount of adhesive on a piece of tape, leading to slippage or lost binding
altogether.
It was thought that certain combinations of the hs1.2 polymorphism would
correspond to the expression of certain isotypes, but this data cannot support that
conclusion. Expression of IGH did not seem to correlate to any particular combination of
polymorphisms and two clones that had the same genotype had different IGH
expression patterns. There are ambiguities in this model system that might be obscuring
any direct relationship between hs1.2 polymorphism genotype and Ig expression. The
CL-01 cells have a chromosomal translocation of the 3’IghRR to the c-myc oncogene
which contributes to their immortalization. So, a functional and non-functional 3’IghRR
are present in the cells and the CRISPR gene editing would target both. At this time, it is
unknown if the functional or non-functional allele has been edited for any given clone.
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Even if it appears that both alleles have been edited, for example if the genotyping
shows four repeats for α2 and one for α1, there could be indel mutations in either allele
not visible on the agarose gel. So that four repeats in the α2 might appear to be a WT
hs1.2 enhancer but it could actually have a disrupted binding site due to an indel
mutation at the CRISPR cut site. Unfortunately, it would be impossible to know if such a
mutation had occurred in the functional or non-functional allele without more thorough
sequencing than is currently available for this project.
One of the more significant findings from editing the hs1.2 enhancer comes from
clone 2-F3, which appears to have had the α1 hs1.2 enhancer completely deleted. If this
proves to be the case (efforts to confirm the deletion are underway) then it would
reveal a surprising role for the α1 hs1.2 enhancer in the expression of the downstream
cluster of constant regions. It had been assumed that the α 1 3’IghRR controlled
expression of the upstream constant regions and the α 2 3’IghRR controlled expression of
the downstream constant regions. These results call that assumption into question
because in the absence of the hs1.2 enhancer clone 2-F3 expressed virtually no ε
transcripts. This finding could be of clinical significance because blocking the activity of
the α1 hs1.2 enhancer could reduce IgE expression and help reduce symptomology of
autoimmune disorders and allergies. However, as described previously, although the α 2
hs1.2 enhancer appears to be WT (four IS repeats) it might actually have an
undetectable mutation, which could account for the low ε expression. Further analysis
of these genotypes must be done to provide a more thorough analysis of hs1.2
enhancer activity in these clones.
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Conclusions and Future Directions
In conclusion, the 53 bp hs1.2 polymorphism has a profound influence on the
expression of IGH isotypes, although the precise mechanism whereby the hs1.2
polymorphism influences Ig expression and leads to human disease states remains
elusive. It is also clear that CRISPR-mediated gene editing is a viable method for studying
the activity of the 3’IghRR. The development, and further refinement, of this technology
allows for the unprecedented direct analysis of the human 3’IghRR without the need for
luciferase reporter plasmids. Further work on the edited clones should investigate their
sensitivity to TCDD treatment. Since specific aim 1 has revealed the NF1 binding site to
significantly influence TCDD sensitivity of the hs1.2 enhancer, any clone that has an
indel mutation in the NF1 binding site might have a lower sensitivity to TCDD. But since
the NF1 binding site is found within the hs1.2 polymorphism any of the edited clones
might exhibit altered TCDD sensitivity. Advances in sequencing technology should make
it possible to further elucidate the specific genotypes of the edited clones, which might
shed more light on the relationship between the hs1.2 polymorphisms and IGH
expression. This project should also be repeated in other human B-cell lines since
cultured, immortalized cells can sometimes behave abnormally. However, any other cell
line used in this type of experiment needs to have maintained the ability to undergo
class switch recombination in order to fully explore 3’IghRR function.
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VI. Materials and Methods

Model Systems and Culture Conditions
The CH12.LX cell line was generously supplied compliments of Dr. Geoffrey
Haughton (University of North Carolina, Chapel Hill, NC). The CL-01 human cell line was
purchased from Novus Biologicals (Littleton, CO). Cells were cultured at 37°C in a 5% CO2
atmosphere and grown in RPMI-1640 (Mediatech, Herndon, VA) enhanced with 2 mM Lglutamine, 10% bovine calf serum (Hyclone, Logan, UT), 13.5 mM HEPES, 0.1 mM
nonessential amino acids, 1.0 mM sodium pyruvate, 100 units/ml penicillin, 100 μg/ml
streptomycin, 50 μM β-mercaptoethanol and 23.8 mM sodium bicarbonate.

Specific Aim 1 Reporter Plasmid Constructs
The human polymorphic plasmids were constructed using a pGL3 basic luciferase
reporter backbone (Promega, Madison, WI) containing ampicillin resistance and the
luciferase gene. The enhancerless variable heavy chain promoter (V H) plasmid and the
α1A plasmid were a generous gift from Dr. Michel Cogné (Université de Limoges, France)
(Denizot et al., 2001; Fernando et al., 2012). Site-directed mutagenesis of the α1A
plasmid was performed as described previously (Fernando et al., 2012). Plasmid DNA
was isolated from transformed colonies and sequenced to ensure quality and accuracy
of the mutations (Retrogen, Inc., San Diego, CA). Mutations included the AP-1, NFκB,
DRE, Oct, AP1.ETS, NF1, 5’ SP-1 or 3’ SP-1 sites and were termed α1AAP1mut,
α1ANFκBmut, α1ADREmut, α1AOctmut, α1AAP1.ETSmut, α1ASP-1.1mut and α1ASP-1.2mut,
respectively (Table 1). Additionally, the invariant sequence (IS) was deleted from the α 1A
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(α1AISdel) and mutants containing the IS deletion plus the Oct mutation
(α1AISdelOctmut) as well as a DRE and NF-κB mutation (α1ADRE.NFκBmut) were also
generated. Mutations of transcription factor binding sites were designed based on
previous electrophoretic mobility shift assay data and motif analysis with TFSEARCH, an
online transcription factor profile database (Grant et al., 1995; Heinemeyer et al., 1998;
Lenardo, Pierce, & Baltimore, 1987; Yao & Denison, 1992).

Specific Aim 2 Reporter Plasmid Constructs
The entire 5 kb sequence from hs3 to hs1.2 was constructed by a commercial
gene manufacturing company called Genscript (Piscataway, NJ). The sequence used for
the plasmid was based on human sequencing results generously provided by Dr. D.
Frezza (University of Tor Vergata). This sequence was inserted into the enhancer region
of a pGL3 luciferase reporter containing the V H promoter and could be used in
experiments without the hs4 enhancer if desired. In step-wise fashion, the hs4 enhancer
was then inserted 3’ of the hs1.2 enhancer, but without any intervening sequence.
Restriction digests, as well as sequencing results, confirm the presence of the inserted
3’IghRR. Two promoters were selected for insertion into the plasmid. One was the γ3
promoter, which contains a potential DRE, AhR binding site. The other was the ε
promoter. The sequences for these promoters were constructed by Genscript, based on
published papers, and inserted into the multiple cloning site (Hu et al., 2000; Kim,
Edmonston, Wu, Schaffer, & Casali, 2004).

78

Specific Aim 3 CRISPR Plasmids
CRISPR plasmids were purchased from Origene (Rockville, MD) in either a
standard plasmid form (pCas-Guide-EF1a-GFP) or as a lentiviral vector (pLenti-CasGuide). The plasmids were cut using restriction enzymes BamHI and Esp3I (an
isoschizomer of BsmBI) and the cut plasmids were purified from a 1% agarose gel in
preparation for cloning the targeting sequences (Table 2). The targeting sequences were
inserted into the cut plasmids using T4 ligase (Promega) and the ligated plasmids were
transformed into chemically competent E. coli (Zymo). Isolated colonies were plucked
from an LB agar plate, grown in a 3 ml culture using LB broth, and the plasmids
extracted via miniprep (Zymo). The minipreps were screened for successful insertion of
the targeting sequence by DNA sequencing (Retrogen). When a successfully cloned
plasmid was identified a transfection-quality preparation of the plasmid was created
using an endotoxin-free Qiagen maxiprep kit.

Use of the CRISPR Plasmids
The pCas-Guide-EF1a-GFP plasmid was transfected into CL-01 cells as previously
described. The transfected cells were allowed to incubate for 72 hours at a
concentration of 1 x 105 cells/ml and were then sorted for GFP expression by the
Research Flow Cytometry Core at Cincinnati Children’s Hospital. Cells expressing GFP
were seeded into a 96 well plate at 1 cell/well. When the cells outgrew the 96 well plate
they were transferred to a 24 well plate. When sufficient cells numbers were achieved
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to sample their DNA, a portion of the cells were used in a genomic DNA extraction
(Zymo) which was then used in a genotyping PCR.
Following insertion of the targeting sequence, the pLenti-Cas-Guide plasmid was
packaged into infectious lentiviral particles by the Cincinnati Children’s Hospital viral
core. Two separate viruses were produced; one which targeted the 5’ end of the α1
3’IghRR and one which targeted the 3’ end. Equal volumes of the two viruses were
mixed together and 500 µl of this mixture was used to re-suspend 2 x 106 CL-01 cells,
which were incubated for 6 hours in the viral mix. After the incubation period, another
500 µl of the viral mix was added to the cells and they were incubated overnight. The
next day, the infected cells were seeded in a 96-well plate at a concentration of 0.5
cells/well. Eight 96-well plates were prepared in total. Half of the plates contained 4
µg/ml polybrene. Two plates which contained polybrene and two that did not were
treated with additional 10 µl of viral mix. All the plates were returned to the incubator
and the cells were permitted to grow until DNA could be isolated for genotyping as
described previously.

Genotyping the Genetically Edited Cells
To genotype the hs1.2 enhancer 100 ng of DNA was added to a PCR mix
containing 1x standard taq buffer (NEB), 10 mM dNTPs (ThermoFisher), 10 µM forward
and reverse primers (Table 1, Eurofins), standard taq (NEB), and nuclease-free water.
Cycling conditions followed a touchdown PCR format with an initial denaturation of 95oC
for 30 seconds followed by a three step cycle of 95oC for 30 seconds, 75oC for 45
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seconds, and 68oC for 30 seconds repeated 8 times with the annealing temperature
decreasing 1oC after every cycle. After 8 cycles, the program changed to a new three
step cycle of 95oC for 30 seconds, 67oC for 45 seconds, and 68oC for 30 seconds
repeated for an additional 27 cycles followed by a final extension step of 68 oC for 5
minutes. Expected product sizes are 209 bp for one IS repeat, 264 bp for two repeats,
319 bp for three repeats, and 374 bp for four repeats. Products were separated on a 2%
agarose gel.
To genotype for the presence/absence of the α 1 3’IghRR following attempts to
delete it 100 ng of DNA was added to a PCR mix containing 1x standard taq buffer (NEB),
10 mM dNTPs (ThermoFisher), 10 µM forward and reverse primers (Table 1, Eurofins),
standard taq (NEB), 3% DMSO, and nuclease-free water. Cycling conditions were 95oC
for 30 seconds followed by a three step cycle of 95oC for 30 seconds, 62oC for 30
seconds, and 68oC for 30 seconds repeated 40 times followed by a final extension step
of 68oC for 5 minutes. Two products are expected for wild type cells of 500 bp for a
product encompassing the 5’ CRISPR targeting site and 400 bp for the 3’ targeting site. If
the α1 3’IghRR is successfully deleted a single product of 300 bp will form. PCR products
were separated on a 2% agarose gel.

Sequencing the Genotyping PCR Products
Sequencing of all genotyping PCR products was attempted, but success was
limited. Three methods were employed to sequence the products. In the first method,
the PCR products were purified from the agarose gel and then cloned into the pGEM-T
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Easy vector (Promega). The cloned vector was transformed into bacteria and isolated
colonies representing a single PCR product were cultured, miniprepped, and the
resulting plasmid DNA sequenced by Retrogen, Inc. The second method employed was
the same except the products were not separated on a gel. Instead, an enzymatic cleanup called ExoSAP-IT (Affymetrix) was performed to digest all unincorporated nucleotides
and the resulting mixture was cloned into the pGEM vector. The final method involved
extracting the separated products from a gel and attempting to sequence the product
directly without cloning it into a vector.

Stimulation of hs1.2 Edited Cells
CL-01 cells which were successfully edited in the hs1.2 enhancer were assessed
for antibody expression following stimulation by CD40 ligand and IL-4. The CD40 ligand
was used at a concentration of 6.25 ng/ml and the IL-4 was used at 25 ng/ml. Cells were
treated at a concentration of 1 x 10 5 cells/ml and incubated for 96 hours. After
incubation, the cells were pelleted by centrifugation and the supernatant was used for
an ELISA while RNA was extracted from the cell pellet.

RNA Extraction and Real Time PCR
RNA was extracted from the cells using Tri-Reagent (Sigma) according the
manufacturer’s protocol. The RNA was converted to cDNA using a cDNA synthesis kit
(Bio-Rad). Real time PCR was performed on 100 ng of cDNA using the Luminaris Real

82

Time Mastermix (Thermo) and cycling conditions followed the manufacturer’s
recommendations. Primers used for RT-PCR can be found in Table 1.

Sandwich ELISA
ELISAs were performed using supernatant from stimulated and naïve cells as
described previously (Sulentic et al., 1998, 2000). Briefly, 100 µl of supernatant was
added to a 96 well plate coated with a human Ig capture antibody. A secondary
antibody specific to either IgM or IgG and bearing an HRP tag was then added to the
plate after incubation and washing. Colorimetric analysis followed the addition of TMB
and sulfuric acid.

Transient Transfections and Luciferase Assays for Reporter Plasmids
Transient transfections and luciferase assays were performed as described
previously (Fernando et al., 2012; Sulentic et al., 2004). Briefly, 1 x 107 CH12.LX or CL-01
cells were transfected with 10 μg of reporter plasmid by electroporation then aliquoted
into appropriate treatment groups and incubated for 24 hours at a seeding
concentration of 2 x 105 cells/ml. Following incubation, the cells were separated from
the media by centrifugation and resuspended in reporter lysis buffer (Promega,
Madison, WI) and frozen for at least one hour at -80oC. After thawing and centrifugation
to remove cell debris 20 μl of sample lysate was mixed with 100 μl of luciferase
substrate reagent and measured by a single-tube luminometer (Promega, Madison, WI,
Berthold Detection Systems, Oak Ridge, TN). Transfection efficiency was determined
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using RT-PCR on DNA extracted from transfected cells using methods described
previously (Sulentic et al., 2004). The forward and reverse primers are 5’ACTGGGACGAAGACGAACACTT-3’ and 5’-TCAGAGACTTCAGGCGGTCAA-3’, respectively.
Sample PCR data was compared to a standard luciferase reporter plasmid with
concentrations ranging from 0.1 ng/μl to 1x10-6 ng/μl. Amount of transfected plasmid
(ng) was calculated by taking the concentration of DNA from the PCR results (ng/μl) x
the volume of DNA added (2μl) x the fold dilution (Fernando et al., 2012). Number of
plasmids per cell was calculated from the equation: [ng of plasmid DNA x number of
plasmids/ng] ÷ total number of cells isolated (previously described in (Sulentic et al.,
2004)). Luciferase activity was normalized to plasmids per cell.

Statistical Analyses of Data
Comparisons between treatment groups (n=3) of the same reporter plasmid
were analyzed using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post
test. Significant differences in luciferase activity (mean ± SEM) normalized to
transfection efficiency were compared to the corresponding vehicle control and
represented by “*”, “**”, “***” at p<0.05, p<0.01 and p<0.001, respectively. Differences
in TCDD-induced fold change compared to vehicle control was determined in the same
manner and denoted by “‡”, “‡‡”, “‡‡‡” at p<0.05, p<0.01 and p<0.001, respectively.
Differences in luciferase activity or fold change between reporter plasmids were
analyzed using a 2-way ANOVA with Bonferroni post test. Daggers, “†”, “††”, “†††”,
denote significant differences between different reporter plasmids at p<0.05, p<0.01
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and p<0.001, respectively. The TCDD-induced fold change results represent the mean
fold change from at least three separate experiments (mean ± SEM). RLU data was
normalized to transfection efficiency.
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Table 1. Primers used for site-directed mutagenesis of the hs1.2 reporter plasmid.
Sequences listed in the table are forward primers. Reverse primers are the reverse
complement of the forward primer. Nucleotides that were mutated are bold and
underlined.
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Table 2. CRISPR/Cas9 targeting sequences. These targeting sequences were cloned into
the CRISPR plasmids (Fig. 13) following the manufacturer’s instructions. “Alpha1-5’Trgt”
and “Alpha1-3’Trgt” represent the sequences which bind to the 5’ and 3’ end of the α1
3’IGHRR, respectively. “NF1cut” targets the polymorphism within the hs1.2 enhancer
and introduces a double strand break in the NF1 binding site. “DREcut” is the same,
except it creates a break in the DRE binding site. The NF1 and DRE targeting CRISPRs
were used independently and generated similar results, although the DRE CRISPR
created edited clones with less efficiency.
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